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Miconazole and clotrimazole are environmentally-persistent drugs that are entrained into crop soils 
through the application of biosolids. There is concern that environmental exposure to such azole 
antifungals, which inhibit fungal growth by disrupting the production of the fungal cell membrane 
component ergosterol, promotes resistance in clinically or agriculturally relevant fungi. Thus, 
either environmentally-relevant or excessive levels of these drugs were applied to microplots over 
ten years and compared with drug-free plots. Overall, ergosterol quantification, plates counts, and 
identification of >250 fungal isolates showed lower fungal counts and species richness in plots 
receiving excessive drug amounts. In addition, fungi from treated plots did not show increased 
resistance to a panel of medical and agricultural azole drugs in disk diffusion assays. Altogether, 
while the highly contaminated soils showed lower fungal counts, lower species richness, and fewer 
isolates highly-susceptible to miconazole, increased resistance to azoles was not evident at 
environmentally relevant concentrations. 
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Summary for Lay Audience 
 
Products sold to treat fungal infections –such as those of the hair, skin, nails, and urogenital tract– 
include drugs that specifically kill or slow the growth of fungi. These products tend to be washed 
down the shower, sink, or toilet and make their way into the sewage system. Following sewage 
treatment, some traces of drugs remain, and two medical antifungal drugs that particularly 
accumulate and persist in the environment, possibly due to their use in over-the-counter products, 
are clotrimazole and miconazole. Although not used to treat systemic infections, these drugs, 
which are chemically defined as azoles, are chemically related to azoles used to treat life-
threatening, systemic fungal infections and agricultural azoles used to control crop diseases in 
agriculture. This reliance on azole products has raised concerns over azole contamination of the 
environment, resulting from the application of biosolid fertilizer derived from sewage treatment 
products onto soils. More specifically, there is concern that azole contamination of soils can shift 
the soil fungal community's population structure and lead to the selection of azole-resistant 
phenotypes. 
 
To address these concerns, from 2010 to 2020, amounts of clotrimazole and miconazole typical to 
those found in biosolid fertilizer were annually added to 2 m2 plots of soil grown with soybeans. 
Soil from these microplots, in addition to identical microplots receiving no drugs, were sampled, 
starting in 2018, for fungal isolation. The resulting fungal libraries were analyzed for changes in 
composition between the control and treated microplots. In addition, fungal libraries from the 
treated plots were compared to libraries from the control plots for their susceptibility to 
clotrimazole, miconazole, medical azoles used for systemic infections, and agricultural azoles used 
for crop protection. 
 
Overall, it was found that the azole-treated soils showed lower fungal counts compared to the 
untreated soils and the soils treated with excess clotrimazole and miconazole showed lower species 
richness. On the other hand, there was no clear evidence that the fungal community recovered from 
the azole-contaminated soils were less susceptible to azoles than fungi recovered from the control 
plots. Nonetheless, several species with medical and agricultural significance were recovered from 
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1 Introduction and Literature review 
 
1.1 History and use of antifungal agents 
 
Although the practice of treating microbial infections with biological preparations dates back to 
ancient cultures, German physician Paul Ehrlich kickstarted research into the synthesis of 
antimicrobial compounds derived from dyes in the early 1900s. However, possibly due to the 
relative rarity of fungal infections prior to the HIV/AIDS epidemic and lack of fungal targets that 
are not shared with humans, the development of antifungals lagged behind the development of  
antibacterials (Larkin et al., 2019). Nonetheless, ergosterol, an essential fungal cell wall 
component not found in human cells, was found to be a suitable molecular target for the polyene 
and azole classes of antifungal drugs (Dixon & Walsh, 1996). Thus, during the 1940’s to 1950’s, 
treatment for fungal infections transitioned from relying on physical interventions, such as 
radiation therapy, and repurposed medications, such as potassium iodide and sulfonamide 
antibiotics, to pharmaceuticals designed for a fungal-specific mode of action (Larkin et al., 2019).  
 
The polyene drugs are defined by macrocyclic rings containing polyene structures, which consist 
of multiple alternating single carbon-carbon and double carbon-carbon bonds, and are 
amphiphilic, meaning that they have hydrophilic and hydrophobic regions. These drugs primarily 
work by binding to ergosterol on the fungal cell surface, which results in the formation of pores 
through which cytoplasmic contents can leak through (Dixon & Walsh, 1996). Nystatin and 
amphotericin B, both isolated from Streptomyces species in 1950 and 1955, respectively, entered 
clinical use in the late 1950’s (Larkin et al., 2019).  
 
Subsequently, the azole drugs clotrimazole, miconazole, and econazole were developed and 
entered the market from the late 1960’s to the early 1970’s (Larkin et al., 2019). Azole drugs bind 
to and inhibit the enzyme lanosterol 14 α-demethylase (CYP51A1), which catalyzes the 
demethylation of lanosterol to ergosterol (Dixon & Walsh, 1996). Effects of this disruption include 
reduced membrane fluidity due to the absence of ergosterol, the build-up of toxic 14α-methylsterol 
by-products, and, possibly, an increase in saturated fatty acid content in the membrane leading to 
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further reduced membrane fluidity (Dixon & Walsh, 1996; Larkin et al., 2019). In addition, at 
higher concentrations than those that produce effects via CYP51A disruption, azole drugs have an 
immediately lethal effect through direct membrane damage to both eukaryotic and prokaryotic 
cells (Van den Bossche et al., 1983). Chemically, azoles are compounds defined by a five-
membered ring containing two nitrogen atoms for imidazoles, or three nitrogen atoms for triazoles 
(Dixon & Walsh, 1996).  
 
It has been estimated that while infectious diseases were the cause of one death per thousand deaths 
in the pre-antibiotic era of the 1940’s, the age-standardized rate dropped to 0.1 per thousand in the 
1970’s due to widespread adoption of antibiotics (Griffiths & Brock, 2003). While the societal 
benefit of antifungal drugs has been less quantified than those of antibacterial drugs, the 
development of antifungal drugs has undoubtedly reduced the mortality rate associated with 
immunodeficiency and reduced the burden of dermatological fungal infections. For example, in a 
model of 40-year old patients with acute myeloid leukemia, it was estimated that prophylactic 
fluconazole administration approximately halved the probability of developing a fungal infection, 
from 0.157 to 0.076, and also slightly reduced the probability of dying from the infection, from 
0.285 to 0.238, for an overall increased life expectancy of 0.9 years (Nomura et al., 2006). 
 
 
1.2 Clinical, community, and agricultural use of antifungals 
 
As of 2019, the World Health Organization List of Essential Medicines includes the imidazoles 
clotrimazole and miconazole (Figure 1), which are suitable for oral and topical use, and the second-
generation triazoles fluconazole, itraconazole, and voriconazole (Figure 2), which are suitable for 
intravenous use (World Health Organization, 2019). In addition, the polyenes, nystatin and 
amphotericin B, and squalene monooxygenase inhibitors, such as terbinafine, are included  (World 
Health Organization, 2019). Other effective antimycotic agents on the list include inorganic 
compounds, such as selenium sulfide and sodium thiosulfate, and small molecules that inhibit 
intracellular fungal targets, such as griseofulvin and flucytosine, which inhibit tubulin and 




   
Figure 1 – Structures of select medical imidazoles 
Clotrimazole (A) and miconazole (B) are medical imidazoles. Each is found as the active 
ingredient in around 300 over-the-counter products in Canada to treat athlete’s foot (tinea pedis), 
jock itch (tinea cruris), ringworm (tinea corporis), superficial yeast growth on skin (tinea 
versicolor), a well as vaginal yeast infections and diaper rash (Wishart et al., 2018). Clotrimazole 
can be prescribed or found in over-the-counter medications in forms such as topical creams 
(typically 10 mg/g) and 10 mg lozenges. Miconazole is found in slightly higher concentrations for 
creams (20 mg/g) and tablets (50 mg) (Wishart et al., 2018). Neither medication is approved for 
systemic use. 
 
   
Figure 2 – Structures of select medical triazoles 
Fluconazole (A) is a medical triazole used for the treatment of cryptococcal meningitis, Candida 
infections of various types, such as vaginal, systemic, and esophageal, as well as prevention of 
fungal lung disease in susceptible populations. It is available by prescription for intravenous use 
(2 mg/mL) and by prescription or over-the-counter in the form of 50-200 mg tablets. Voriconazole 
(B) is prescribed for intravenous use (10 mg/mL), and in tablet form (50-200 mg); however, it is 
not available over the counter (Wishart et al., 2018). It is approved for use for esophageal 
candidiasis in addition to invasive aspergillosis, which is intrinsically resistant to fluconazole 
(Leonardelli et al., 2016), and Fusarium infections, which are resistant to fluconazole and 
itraconazole (Stanzani et al., 2007). Itraconazole (C) is not available over-the-counter or for 
intravenous use but can be prescribed for tablet/capsules (65-200 mg) and as an oral solution (10 
mg/mL). Itraconazole is approved for a wider variety of fungal infections, including 
blastomycosis, histoplasmosis, aspergillosis, and onychomycosis, as well as preventing fungal 
infections in cystic fibrosis patients (Wishart et al., 2018). 





According to the Medical Expenditure Panel Survey compiled by the U.S. Department of Health 
and Human Services, Agency for Healthcare Research and Quality, fluconazole was the most 
widely prescribed antifungal drug with 3.5 million annual prescriptions in the U.S. in 2017, 
followed by nystatin and ketoconazole, another medical imidazole, with 2.5 million prescriptions 
each (Agency for Healthcare Research and Quality, 2018). Less commonly prescribed antifungal 
drugs include clotrimazole, alone or in a mixture with the anti-inflammatory drug metamethasone, 
at 1 million and 850,000 annual prescriptions respectively, terbinafine at 1 million prescriptions, 
and miconazole with 225,000 prescriptions (Agency for Healthcare Research and Quality, 2018).  
 
1.3 Fate of antifungals in the environment 
 
Due to previous studies implying that soil environments can act as a reservoir of azole-resistant 
fungi that can cause mycosis in humans, it is essential to determine what concentration of azole 
drugs in the soil can promote antifungal resistance. Pathways leading to azole contamination of 
soils include applying agricultural antifungals to product crops against plant-pathogenic fungi, 
such as difenoconazole, tebuconazole, and propiconazole (Figure 3), as well as the application of 
antifungal-contaminated biosolids to agricultural lands.  
     
Figure 3 – Structures of select agricultural triazoles 
Difenoconazole (A), tebuconazole (B), and propiconazole (C) are broad-spectrum fungicides 
approved for use in Canada to control fungal growth on turfgrass, wood, and crops such as cereals. 
To control plant pathogens, these agricultural triazoles can be applied via foliar application or seed 
treatment (Pest Management Regulatory Agency, 2016c, 2016b, 2016a). 
 
During primary treatment of wastewater, solids are allowed to settle, and these solids are then 
biologically digested to create biosolids. Biosolids are then applied to agricultural fields as sources 
         
        
        
        








A B C 
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of nutrients, such as nitrogen and phosphate, and micronutrients, such as copper, iron, 
molybdenum, and zinc. In Ontario, the application of biosolids to agricultural fields is governed 
by stringent regulations that consider parameters such as field slope, distance to residential areas, 
and amounts of plant-available nitrogen and phosphate (Government of Ontario, 2002). 
 
A 2007 survey of Swedish sewage treatment plants estimated that 41% of purchased miconazole 
and all purchased clotrimazole could be accounted for in sewage sludge (Lindberg et al., 2010). 
Furthermore, miconazole has previously been detected at concentrations of 477 μg/kg and 341 
μg/kg in biosolids originating from Niagara Region sewage treatment facilities (Sabourin et al., 
2012) and the Robert O. Pickard Environmental Centre in Ottawa (Gottschall et al., 2012), 
respectively. Clotrimazole was detected at a concentration of 492 μg/kg in biosolids originating 
from a Beijing sewage treatment plant (Chen et al., 2013).  
 
Following the application of biosolids, miconazole and clotrimazole persist in soils. A 
concentration of 127 μg miconazole/kg soil was detected 400 days following application of the 
Ottawa biosolids to a field at a rate of 22 Mg dry weight per ha (Gottschall et al., 2012). Likewise, 
plots receiving three annual applications of the Beijing biosolids at a rate of 60 Mg/ha contained 
up to 65 and 41 μg miconazole and clotrimazole, respectively, per kg of soil (Chen et al., 2013). 
Microcosm studies have shown that the half-life of clotrimazole decreases with temperature, with 
a half-life in loam soil of 275 days at 4°C and 68 days at 30°C (Sabourin et al., 2011). In addition, 
in sludge-amended sandy-loam soil, the half-life of clotrimazole decreased from 126 to 29 days, 
as moisture content increased from 4.5 to 11% (García-Valcárcel & Tadeo, 2012) 
 
1.4 Emergence of resistance to antimicrobial agents 
 
The Centers for Disease Control and Prevention published in its Antibiotic Resistance Threats in 
the United States, 2019 report that over 2.8 million cases of antibiotic-resistant infections—mostly 
caused by bacteria—in the U.S. were causing over 35,000 deaths per year  (CDC, 2019). Multiple 
factors lead to the evolution, selection, and spread of antibiotic and antifungal resistance. These 
include the ability of the microorganisms to develop resistance due to over-use or inappropriate 
use of antibiotic or antifungal drugs, the spread of drug-resistant strains in environments such as 
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hospitals, and, in bacteria, the spread of genes conferring drug-resistance to drug-susceptible 
bacteria via plasmids, bacteriophages, or uptake of naked DNA (Levy, 2002). More specifically, 
fungi can develop resistance to azole drugs via upregulation of drug and toxin-removing efflux 
pumps, upregulation of CYP51A1-encoding genes, and modifications of the CYP51A1-azole 
binding sites (Fisher et al., 2018).  
 
The development of resistance to fluconazole, the most commonly prescribed azole drug, is 
exacerbated by the fact that fluconazole is fungistatic and not fungicidal, thus allowing for 
directional selection of the resistant phenotype among exposed isolates, and the fact that 
fluconazole resistance can occur by multiple mechanisms (Anderson, 2005). It follows that the 
international ARTEMIS Antifungal Surveillance Program detected that fluconazole resistance in 
the yeast Candida glabrata increased from 9% to 14% from 1992–2001 to 2001–2007 (Pfaller, 
Messer et al., 2009). In addition, from 2005 to 2007, increases in voriconazole resistance in 
multiple clinical species of Candida have been found, including in C. famata (from 1% to 6%), C. 
norvegensis (0% to 7%), C. lipolytica (0% to 11%), and C. pelliculosa (14% to 17%) (Pfaller et 
al., 2010). In addition, Candida auris is a multi-azole resistant pathogen first isolated in 2009; 
however, it has been argued that the recent spread of the species may be due to climate change as 
opposed to azole overuse (Casadevall, 2019). 
 
1.5 Evidence of cross-resistance between azoles 
 
Several in vitro studies have shown that the evolution of resistance to one azole, whether used for 
agricultural or clinical purposes, leads to increased resistance to other azoles. For example, 
following gradual adaptation of up to 30 μg/mL tebuconazole over eight weeks, the maize 
filamentous fungal pathogen Colletotrichum graminicola showed increased resistance to 
clotrimazole and miconazole in a skin infection assay (Serfling et al., 2007). Likewise, isolates of 
the plant pathogen Ustilago avenae selected for resistance to the agricultural azole tetraconazole 
were also more resistant to clotrimazole, miconazole, and itraconazole than unadapted isolates 
(Köller & Wubben, 1989). Another study showed that a Candida parapsilosis strain selected for 
lower sensitivity to tetraconazole was also less sensitive to fluconazole, voriconazole, and 
itraconazole (Rocha et al., 2016). Simultaneous incubation with promethazine, an efflux pump 
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inhibitor, did not lower the minimum inhibitory concentration (MIC) values to fluconazole, 
leading to the suggestion that increases in efflux pump activity could not solely be responsible for 
the increased resistance to fluconazole after tetraconazole adaptation (Rocha et al., 2016).  
 
A recent study applied spores of triazole-susceptible A. fumigatus containing an antibiotic-
resistance marker and tebuconazole to open fields and greenhouse soil planted with tomatoes (Cao 
et al., 2020). After four fungicide applications ov40 
r fourteen days, the open fields contained up to 0.72 mg tebuconazole/kg soil, and the greenhouse 
soil contained up to 1.24 mg/kg soil. When A. fumigatus strains containing the antibiotic-resistance 
marker were isolated and tested for sensitivity against azoles, a higher number of triazole-resistant 
isolates were recovered from the greenhouse soils, and this was hypothesized to be due to the 
higher tebuconazole concentration. It was concluded that the tebuconazole exposure could induce 
resistance to the medical triazoles, itraconazole and voriconazole (Cao et al., 2020).  
 
It follows that isolates that show reduced sensitivities to clotrimazole and miconazole following 
long-term exposure will likely show reduced sensitivities to other azole drugs regardless of 
whether they are meant for clinical or agricultural use. 
 
1.6 Antifungal resistance between the environment and the 
clinic 
 
Recent studies have noted genetic similarities between environmental and clinical fungal isolates 
and, thus, have implicated transmission of opportunistic pathogens residing in the environment to 
humans. For example, Candida tropicalis with identical identifying genomic sequences have 
been isolated from soil, fruits, and the bloodstream of azole-naïve candidiasis patients without 
correlation to time and treatment location within the hospital (Chen et al., 2019; Lo et al., 2017). 
In addition, because genetically similar isolates of C. krusei have been observed both in clinical 
settings and various environmental settings, these isolates were likely transmitted from the 
environment to humans (Douglass et al., 2018). These findings have important implications for 
clinical azole resistance as the mentioned C. tropicalis strain identified in environmental and 
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clinical samples had reduced sensitivity to clinical azoles, and C. krusei is intrinsically resistant 
to fluconazole.  
 
Together, these findings beg the question: Is azole-resistance being selected for in the 
environment and then causing azole-resistant mycotic infections in humans? Evidence for such a 
phenomenon comes from clinical isolates of the filamentous fungi species Aspergillus fumigatus 
containing a TR34/L98H or TR46/Y121F/T289A mutation in the Cyp51A-encoding gene. The 
TR34/L98H mutation consists of a 34-bp tandem repeat in the promoter region and a leucine to 
histidine substitution in codon position 98 in the coding region. Meanwhile the 
TR46/Y121F/T289A mutation includes a 46-bp tandem repeat in the promoter region and a 
tyrosine to phenylalanine in position 121 and threonine to alanine in position 289 of the coding 
region. Computer modelling has suggested that the resistant phenotype of the TR34/L98H 
mutant is due to altered binding conformations between azole drugs and the modified Cyp51A 
enzymes (Bowyer & Denning, 2014; Snelders et al., 2012). Strains of A. fumigatus with this 
mutation can outcross with azole-sensitive strains and, thus, spread geographically (Camps et al., 
2012). In addition, microsatellite genotyping studies have dated the origin of the TR34/L98H 
mutation to 1997, shortly after the approval of agricultural azoles such as propiconazole and 
tebuconazole in the early to mid 1990’s (Snelders et al., 2012). As well, the tandem repeats of 
both the TR34/L98H and TR46/Y121F/T289A mutations are typical of azole-resistance 
mutations found in fungal plant pathogens (Chowdhary et al., 2013; Snelders et al., 2009). Given 
these points, it is possible that the two mutations originated in the environment before showing 
up in clinical settings. 
 
It has also been shown that due to high levels of fungicides, such as tebuconazole, 
epoxiconazole, and prothioconazole, waste from flower bulbs, compost waste, and wood 
chippings were identified as being particularly conducive to the development of azole-resistant 
Aspergillus fumigatus (Schoustra et al., 2019). In addition, a case study of an azole-naïve patient 
who developed fatal aspergillosis found genetically identical A. fumigatus strains containing the 
TR46/Y121F/T289A mutation throughout the patient’s house months after death (Lavergne et 
al., 2017). Altogether, these studies are evidence that A. fumigatus can develop azole resistance 
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in the environment and fungi residing in the environment can cause mycotic infections in 
humans. 
 
1.7 Fungal ecology 
 
The largest and best-studied subdivisions of the Dikarya kingdom are the Ascomycota and 
Basidiomycota. Common fungal pathogens include the candidiasis-causing Ascomycete yeasts 
Candida albicans and Candida glabrata, the cryptococcosis-causing Basidiomycete yeasts 
Cryptococcus neoformans and Cryptococcus gattii, and the aspergillosis-causing filamentous 
fungus Aspergillus fumigatus. Collectively these five species accounted for ~80% of fungal 
infections following organ transplants monitored by the American-based Transplant-Associated 
Infection Surveillance Network (Pappas et al., 2010).  
 
With the exception of Candida krusei, detection of other common clinically relevant Candida 
species in environmental samples has been rare and, in the case of C. albicans, not uncommonly 
interpreted as sample contamination (Opulente et al., 2019). Likewise, clinically relevant yeasts 
have been described as ‘not common or abundant’ in soils (Yurkov, 2018). However, Opulente et 
al. succeeded in obtaining 28 isolates, including major Candida pathogens –C. albicans, C. krusei, 
C. parapsilosis, and C. tropicalis—from 931 samples of soil, plant matter, and fruits. Although 
the study could not determine if the Candida isolates could actively grow in soil, their isolation 
from soils proved that they persist outside of endothermic environmefnts and could possibly be 
transferred between endothermic organisms via soil (Opulente et al., 2019). Another study from 
2019 questioned the long-held assumption that views C. albicans as an obligate commensal of 
endothermic animals (Bensasson et al., 2019). In this work, the authors isolated three strains of C. 
albicans from oak trees and suggested that the organisms were long-term inhabitants of the trees 
based on their high genetic diversity (Bensasson et al., 2019). On the other hand, the filamentous 
fungus A. fumigatus is readily isolated from environmental samples (for example, see Snelders et 
al., 2009). 
 
Soil bacterial communities are typically more diverse and contain 2-3× the species richness 
compared to soil fungal communities (Peay et al., 2016). In addition, yeasts tend to be less 
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abundant than filamentous fungi in soils with counts of yeasts typically being in the range of 
hundreds to thousands of cells per gram (Yurkov, 2018). Nonetheless, soil fungi play important 
ecological roles, such as organic matter decomposition and nutrient mineralization. Globally, 
proximity to the equator and available nitrogen correlates with pathogen richness, moisture-related 
parameters correlate with saprotroph richness, and soil alkalinity and the presence of host plants 
correlates with ectomycorrhizal richness (Tedersoo et al., 2014). In addition, fungal biomass and 
diversity were shown to be associated with increases in nitrogen and nitrate concentration in 
grassland and forest soils in Germany (Birkhofer et al., 2012). Below topsoil, species richness 
broadly decreases with decreasing carbon availability, leaving mycorrhizal fungi and species able 
to break down lignin and tannin predominating lower depths of soils (Peay et al., 2016). Fungal 
communities in agricultural soil samples can also be influenced by factors such as tillage practice, 
fertilization intensity, and crop growth. For example, Fusarium spp. was found to be positively 
associated with conservation tillage while Rhodotorula spp. was positively associated with 
conventional tillage (Sommermann et al., 2018). 
 
1.8 Review of Methods 
 
1.8.1 Culture-based surveys of soil fungi 
 
Culture-based surveys of soil fungal communities using a small number of isolation methods tend 
to produce collections dominated by a few species. For example, Aljohani et al. isolated 110 yeasts 
from 443 Cameroonian agricultural soil samples by inoculating 1 mL of chloramphenicol 
containing SD (Sabouraud dextrose) broth with 200 mg soil for 2-7 days at 30°C and then streaking 
the liquid enrichments onto yeast extract-peptone-dextrose agar for 48 hours of incubation 
(Aljohani et al., 2018). The resulting collection was dominated by Cyberlindnera subsufficiens 
(25% of isolates), Cyberlindnera saturnus (14%), Torulaspora globose (19%), and Candida 
tropicalis (18%) (Aljohani et al., 2018). Cyberlindnera and Rhodotorula species were also found 
to dominate in a study of endophytic yeast of the elm and oak trees, Ulmus parvifolia and Quercus 
salicina (Kim & Kim, 2017). Yeasts from the genera Cyberlindnera were also the dominant 
endophytic yeast isolated from the roots of the critically endangered fern Mankyua chejuense (Kim 
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et al., 2017). Enrichment-free protocols can also produce collections dominated by a few species. 
For example, of over 100 yeasts isolated by Slavikova & Vadkertiová from direct plating of a 1% 
soil slurry onto two agars at 7°C and 25°C, 80% belonged to four species (Sláviková & 
Vadkertiová, 2003). 
 
1.8.2 Ergosterol quantification for estimating biomass 
 
Quantification of ergosterol is a useful biomarker of fungal load in environmental samples, 
including soils (reviewed in Djajakirana et al., 1996; Montgomery et al., 2000). As caveats, 
however, ergosterol quantification underestimates counts of yeasts relative to filamentous fungi 
with a single yeast cell showing ergosterol amounts on the magnitude of 1×10-4 pg and a single 
filamentous fungi spore containing 1×10 levels (Pasanen et al., 1999). Also, ergosterol shows 
relatively slow degradation over two months in soils unexposed to sunlight (Mille-Lindblom, 
Wachenfeldt, & Tranvik, 2004) and soils briefly exposed to fungicides (Zhao, Lin, & Brookes, 
2005), complicating the utility of ergosterol for quantifying living biomass. 
 
1.8.3 Antifungal susceptibility testing 
 
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and 
Laboratory Standards Institute (CLSI, previously NCCLS) developed recommendations for testing 
the sensitivity of isolates to clinical antifungal drugs. Both institutions have developed methods 
for antifungal susceptibility testing using broth dilutions. In this method, isolates are grown in 
broths containing various concentrations of a drug and the lowest drug concentration that leads to 
growth inhibition is noted as the minimum inhibitory concentration (MIC). For reference, some 
broths are left uninoculated and some isolates are grown in broths containing no drug. 
 
The EUCAST method for testing yeasts isolates was optimized for testing Candida and 
Cryptococcus species and tests fluconazole from a range of 0.125 to 64 mg/L and itraconazole and 
voriconazole from a range of 0.008 to 4 mg/L. (EUCAST, 2020). In addition, a protocol for 
filamentous fungi was optimized for testing Aspergillus spp. and tests itraconazole from 0.0156 to 
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8 mg/L and voriconazole from 0.0312 to 16 mg/L (EUCAST, 2015). Both protocols are based on 
a 200 μL microbroth dilution assay using RPMI-glucose broth containing 2% glucose. Likewise, 
CLSI recommends similar microbroth dilution tests in its M27-A3 (CLSI, 2008a) and M38-A2 
(CLSI, 2008b) protocols for testing yeasts and filamentous fungi, respectively.  
 
A second method for testing the susceptibility of isolates to drugs involves streaking an agar plate 
with a suspension of an isolate and immediately placing a material containing the drug, such as a 
paper disk, onto the agar. The drug then diffuses outward from the material onto the surrounding 
agar such that the concentration of the drug steadily decreases in the agar with increasing distance 
from the drug-containing material. Following incubation, the distance from the disk at which the 
isolate can no longer grow is used as a measure of the isolates' sensitivity. Agar-based 
susceptibility tests can be quicker to perform than broth-based tests while still providing reliable 
results. Intra- and interlaboratory variation using an E-test strip, which is a plastic strip containing 
a gradient of a drug, on RPMI-glucose agar is relatively low making testing relatively reliable. 
One review where four laboratories performed 20 replicates of E-tests with C. krusei and C. 
parapsilosis isolates tested against ketoconazole and fluconazole showed agreement within a 3 
log2dilution range 98-100% of the time (Pfaller et al., 1996). 
 
Based on disk diffusion methods, CLSI produced the M44-A2 protocol (CLSI, 2009) for testing 
yeasts, which was optimized for testing Candida species against fluconazole and voriconazole, 
and the M51-A method (CLSI, 2010) for testing filamentous fungi. For both protocols, CLSI chose 
to use Mueller-Hinton agar—a complex medium—over RPMI (Roswell Park Memorial Institute) 
agar—a synthetic medium— due to its greater availability and lower cost at the expense of more 
significant batch-to-batch variability (CLSI, 2009). However, the activity of the imidazoles 
clotrimazole and miconazole have been shown to be antagonized by complex media such as SD 
agar and brain-heart infusion agar, but not present in synthetic media (Ester & Hoeprich, 1976).  
 
To ensure reproducibility, the microbroth-based EUCAST 7.3.1 protocol for testing of yeasts 
(EUCAST, 2020) stipulates that the inoculum used for testing must be standardized to 0.5 x 105 to 
2.5 x 105 CFU/mL of distilled water while the microbroth-based EUCAST 9.3.1 protocol for 
testing filamentous fungi (EUCAST, 2015) stipulates an inoculum size of 2 x 105 to 5 x 105 
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conidia/mL. Yeasts are to be grown between 34-37°C on SD or PD agar for 18-48 hours before 
adjusted to a set turbidity using a spectrophotometer. Meanwhile, filamentous fungi can be grown 
for 2-5 days at 35°C, or longer if sporulation does not occur, on any media that encourages 
sporulation. Then, a damp cotton swab is rubbed against filamentous fungi colonies and deposited 
into 5 mL distilled water with Tween 20, a surfactant. Next, to standardize the inoculum size, the 
suspension is either directly adjusted with distilled water after counting conidia using a 
haemocytometer, or the suspension is filtered through an 11 μM filter to filter out hyphae before 
using a spectrophotometer to adjust the density of conidia. 
 
1.9 Objectives and hypothesis 
 
Although numerous studies have raised concerns over residual antibiotics in the environment 
promoting the development of antibiotic resistance in soil bacteria, less is known about the effects 
of residual antifungal drugs on soil fungi. Given that miconazole and clotrimazole persist in the 
environment, microplots at Agriculture and Agrifood Canada London Research and Development 
Centre (AAFC) have been annually amended with environmentally relevant and excessive 
concentrations of miconazole and clotrimazole since 2010. This study aimed to elucidate the 
effects that the miconazole and clotrimazole in these plots have had on fungal community 
composition and antifungal resistance. My predictions were: 
1) Fungal isolates belonging to the same species would show decreased sensitivities to 
clotrimazole and miconazole when isolated from the treated versus the control plots 
2) The fungal community in the soils containing clotrimazole and miconazole would be 
enriched in wildtype strains with intrinsically low sensitivities to the drugs as, over the 
years, the drugs inhibited the growth of sensitive strains  







2.1 Field experiment 
In 2010, a field experiment was initiated at the AAFC-London to evaluate the long-term impact of 
biosolid-typical levels of clotrimazole and miconazole exposure on soil fungi. Annually, in June, 
solutions of 365 mg/mL miconazole nitrate in dimethyl sulfoxide (DMSO) and 500 mg/mL 
clotrimazole in methanol were mixed into four 1 kg portions of soil. These 1-kg portions of soil 
were then mixed into 2 m2 microplots to a depth of 15 cm using a rototiller to produce four replicate 
microplots containing 1 mg/kg soil and four replicate plots containing 10 mg/kg soil of both 
miconazole and clotrimazole. Four replicate plots were left untreated. The plots were randomly 
distributed by treatment type across the field and were physically separated by fibreglass frames. 
The gray-brown Luvisol soil had previously been classified as having the following properties: a 
sand/silt/clay ratio of 18/67/15%, pH of 7.5, cation exchange capacity of 7.5, and organic matter 
content of 3.4%. The soil had no known prior treatment with manure or biosolids, and no known 
treatment with pesticides or fertilizers since 1986. The microplots were cropped annually with 
soybeans (Glycine max var. Harrosoy) and manually weeded. Each spring, eight 20 cm-long soil 
cores totalling 1 kg were collected from each plot. These soil samples were sieved and stored at -
20°C for long-term storage. On the other hand, soil samples were sampled in August and October 
2018, April 2019, and March 2020 and stored at 4°C or 15°C for up to six months prior to being 
used for fungal isolation (Figures 4-6). 
 
2.2 Isolation of yeasts and filamentous fungi 
 
To isolate yeasts and filamentous fungi colonies from the soils, first, soil slurries were prepared. 
To create soil slurries, five grams of each soil sample were measured out using a metal spatula that 
was sterilized with 70% ethanol between samples. The five gram soil aliquots were suspended in 
45 mL of 0.002% sodium metaphosphate buffer (Fisher Scientific, Ottawa, ON) in 50 mL conical 
tubes (Corning Life Sciences, Corning, NY; or Sarstedt AG, Numbrecht, Germany). Soil slurries 
were stored for up to a week at 4°C before being used for fungal isolation. Soil slurries were mixed 
using a wrist action shaker (Burrell, Pittsburgh, PA) before being spiked into various broths or 
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plated onto multiple types of solid agar (Table 1; Figures 4-6). Soil slurries spiked into broths in 
50 mL conical tubes were either rotated on a Roto-Torque (Cole-Palmer, Chicago, IL) or shaken 
at ~250 rpm on a shaker (New Brunswick Scientific, Edison, NJ) to encourage yeast-like growth 
in the supernatant and filamentous fungi to sink down into the pellet. After a brief incubation, 100 
μL of the supernatant was then plated onto solid agar to selectively isolate yeasts. Alternatively, 
100 μL of a 1:10 dilution of slurry or 50 or 100 μL of undiluted slurry was directly plated onto 
various antibiotic-containing agar plates to give 1, 5, or 10 mg of soil plated per agar plate. To 
plate broth supernatants or soil slurries, a metal or glass plate spreader was sterilized in 97% 
ethanol and passed over a flame between spreads. For each plating event, soils from all twelve 
plots were used, and a negative control of either sodium metaphosphate or MilliQ water was used. 
To increase the diversity of isolates and to minimize clonality in the fungal collection, new soil 
slurries were routinely prepared between plating events and in general, only one morphologically 
identical colony per plate was retained for the collection. 
 
Commercially prepared agars used for isolation of yeasts and filamentous fungi from soils included 
dichloran-glycerol 18 agar (DG18) (Fluka, Steinheim, Germany), rose bengal (RB) and yeast-
mold-11 (YM-11) agar (both from Hardy Diagnostics, Santa Maria, CA), and Sabouraud dextrose 
(SD), Mueller-Hinton (MH), malt extract (ME), Czapek-Dox (CZ), and potato-dextrose (PD) agars 
(all from Becton, Dickinson and Company, Sparks, MD). Agars made in-house included 
Dekkera/Brettanomyces differential medium (DBDM) and glucose-yeast-peptone (GYP) agars. 
The PD, MH, and GYP agars were used to support the growth of a wide range of organisms due 
to a nutrient-rich composition and a neutral pH. As for selective media, CZ uses nitrate as a sole 
nitrogen source, DBDM uses ethanol as sole carbon source, ME and SD both have an acidic pH, 
DG selects for osmophilic and xerophilic organisms due to low water activity, and RB agar 
contains rose bengal to inhibit the radial growth of certain filamentous fungi. 
 
All agars and broths were amended with antibiotics to inhibit the growth of bacteria and select 
agars and broth were amended with selective fungicides to increase the diversity of fungi isolated 
overall. Antibiotic stocks of 100 mg/mL chloramphenicol in 97% EtOH, 500 mg/mL streptomycin 
in ddH2O, 5 mg/mL chlortetracycline HCl in 0.5 N NaOH and a stock of 100 mg/mL 
cycloheximide in ddH2O, were prepared in 15 mL or 50 mL conical tubes, filtered using a 0.22 
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μm filter, and stored in conical tubes at 4°C prior to use. All three antibiotics and cycloheximide 
were sourced from Sigma-Aldrich (St. Louis, MO). Antibiotics were added to the agar as noted  
Following initial isolation, in most cases, yeasts and filamentous fungi were sub-cultured to purity 
on the agar used for initial isolation after which axenic yeasts cultures were maintained on 
Sabouraud dextrose (SD) agar and axenic fungal cultures were maintained on Mueller-Hinton 
(MH) agar at room temperature. Yeasts isolated at 4°C were maintained at 4°C, 15°C or room 
temperature, depending on the observed maximum growth temperature. Likewise, filamentous 
fungi that were isolated at temperatures over 37°C were either maintained at 37°C or room 
temperature, depending on the observed growth rate. Preparation of glycerol stocks for yeasts 
varied by the period of isolation (Figures 4-6). On the other hand, filamentous fungal cultures were 
swabbed with sterile cotton swabs from growth on MH agar at room temperature and the resulting 
fungal fragments were suspended in Milli-Q water. The fungal suspensions were then used to 





Table 1 – Composition of Agars and Broths used for Fungal Isolation 
With the exception of commercially-prepared RB and YM-11 agars, agars were either prepared in-house or made with the addition of 
agar base (Biobasic, Toronto, ON) to commercially-prepared broths. All agars contained 15 g/L of agar with the exception of 
commercially-prepared YM-11 agar, which used 13.5 g/L. For enrichment of yeasts, broths identical to YM-11 and RB agar were 
prepared in-house with the exception that trypan blue was not added to the YM-11 broth. An additional medium, termed yeast-extract 
peptone dextrose (YEPD), was prepared identically to GYP media with double the amounts of peptone and L-glucose. pH values of 
media were brought within the ranges shown using 1N NaOH or HCl. 
 
  CZ DBDM DG18 GYP ME MH PD RB SD YM-11 






















Beef extract      2     
Malt extract     6      
Potato extract       4    
Yeast extract    5 1.2      
Nitrogen Source (g/L) 
Caesin, acid digested      17.5     
Peptone, animal sources   5 10     10 20 
Peptone, soy        5  20 
Sodium nitrate 3          






Ethanol (mL/L)  60         
L-Glucose (g/L)   10 20 6  20 10 20 5 
Maltose (g/L)     1.8      
Soluble starch (g/L)      1.5     
Sucrose (g/L) 30          
Inorganic Constituents (g/L) 
Dipotassium phosphate 1         5 
Ferrous sulfate 0.01          
Magnesium sulfate 0.5  0.5     0.5   
Monopotassium phosphate   1     1   
Potassium chloride 0.5          
Sodium chloride          5 
Additives (mg/L) 
Chloramphenicol 80 80 100 80 80 80 80 80 80  
Chlortetracycline HCl          200 
Cycloheximide  100         
Dichloran   2        
Rose bengal        5   
Streptomycin 400 400  400 400 400 400 400 400  




Figure 4 – Isolation Procedure of Yeasts from August 2018 Soils  
Sixteen yeasts were obtained by AAFC technician Andrew Scott (not shown on flowchart) where 
all but one isolate was obtained by direct plating of 10 mg of soil onto 0.2-fold strength (0.2×) SD 
agar with miconazole and clotrimazole, 0.2× SD agar containing cetrimonium bromide (noted by 
the ‘-C’ affix to media names), 0.2× PD, and 0.2× YEPD agars. An additional isolate was obtained 
by performing an enrichment for yeasts with 0.2× SD-C broth and streaking the supernatant onto 
0.2× SD-C agar using a 10 μL loop. For long-term storage, single colonies were amplified in 5 mL 
test tubes at 30℃ with shaking at 250 RPM for 3-7 days using 2 mL of yeast extract-peptone-
dextrose (YEPD) broth. Glycerol stocks were created using 800 μL of the liquid cultures and 800 






Figure 5 – Isolation of Yeasts and Filamentous Fungi from October 2018 Soils 
For long-term storage of yeasts, stocks were created by sub-culturing isolates onto solid agar at least twice using single colonies, and 






Figure 6 – Isolation of Yeasts and Filamentous Fungi from April 2019 Soils 
To create long-term stocks, yeasts were sub-cultured on MH agar at the initial isolation 
temperature, and colonies were scrapped using a 10 μL loop and deposited in 800 μL of 0.9% NaCl 
and 800 μL of 50% glycerol. In addition to the fungi isolated from the above procedures, in 
February 2020, soils stored for three months at 15℃ and then 8 additional months at 4℃ were 
used to isolate 26 yeasts using a two-day enrichment of 30 mg soil in 0.2× Luria-Bertani broth and 
subsequent two-week incubation on 0.2× SD-C agar at room temperature. Seven of these yeasts 
were used for antifungal susceptibility testing. However, these yeasts were were not used for 
species richness calculations as these yeasts were specifically isolated to increase sample size for 
susceptibility testing of yeasts from the treated plots. Six sequenced filamentous fungi were also 








2.3 DNA extraction from fungal isolates 
 
For isolating genomic DNA from yeasts, a protocol modified from Lõoke et al. (2011) was used. 
Briefly, yeast cells were grown for up to one week on SD agar at room temperature or 15℃ and a 
sterile 10 μL plastic loop was used to deposit cells into a lysis solution containing 180 μL of 0.22 
μm filter-sterilized 200 mM lithium acetate (Sigma, St. Louis, MO) and 20 μL of 10% sodium 
dodecyl sulfate in a 1.5 mL microcentrifuge tube. The mixtures were briefly vortexed, incubated 
at 70℃ for up to 10 minutes and then centrifuged at 15,000 × g for three minutes. The resulting 
supernatant was then used as a starting material for use with the Wizard Genomic DNA 
Purification Kit (Promega, Madison, WI). The Isolating Genomic DNA from Yeast protocol 
included in the kit was followed starting from the protein purification step except that all 
centrifugation steps resulting in nucleic acid pellets were performed at 15,000 × g for 10 minutes. 
 
For isolating DNA from filamentous fungi, bead beating tubes from PowerSoil kits (Qiagen, 
Hilden, Germany) were amended with lysis buffer from the kits and half-filled with 50 x 10 mm 
blocks of fungal mass growing on MH agar for at least one week. The tube contents were then 
processed as per manufacturer’s instructions for soil samples. Alternatively, following 
homogenization, bead beating tubes were centrifuged at 15,000 × g for 5 minutes and the 
supernatant was used directly as a template for PCR amplification. 
 
2.4 Identification of isolates 
 
Initially, yeasts were grown on SD agar for up to a week and filamentous fungi were grown on 
MH agar for up to three weeks, both at room temperature, to group isolates by morphology. To 
further group the isolates, DNA was extracted from 88 yeasts representing 15 species and Random 
Amplified Polymorphic DNA (RAPD) PCR was performed based on the methods of Aljohani et 
al. (2018). In this method, PCR is performed using a single primer that amplifies repetitive 
sequences in the genomic DNA and the resulting amplicons are run on an agarose gel to group 
closely related strains. Briefly, in 25 μL PCR strip tubes, 10 μL reactions were composed of 





μM dNTP mix (BBI Biotech, Berlin, Germany), and 1 μM of either the (GACA)4 (5’-
GACAGACAGACAGACA-3’) or M13 primer (5’- GTAAAACGACGGCCAG-3’) (Sigma 
Aldrich, St. Louis, MO), 2 ng/mL DNA, and autoclaved MilliQ water. The reactions were cycled 
using a protocol of denaturation at 98°C for two minutes, amplification for 45 cycles of 93°C for 
20 sec, 50°C for 45 sec, and 72°C for 20 sec, followed by a hold at 72°C for six minutes and a cool 
down to 4°C. The (GACA)4 and M13 PCR products were combined and run on a 1% agarose gel 
at 80V for 1.5-2.5 hours and bands were manually scored. PCR fingerprinting failed for 
filamentous fungi, possibly due to the DNA extraction technique. 
 
Representatives of each fingerprint, as well as each morphologically unique isolate, were identified 
by sequencing ~250 bp of the ITS1 region. The ITS1-F forward (5'- 
CTTGGTCATTTAGAGGAAGTAA-3') (Gardes & Bruns, 1993) and ITS2 reverse primer (5'- 
GCTGCGTTCTTCATCGATGC-3') (White et al., 1990) were used. The template used for the 
PCR was either yeast colonies grown for less than one-week and suspended in MilliQ water 
(ABS600 ~0.2), yeast DNA diluted to 10 ng/mL, or undiluted filamentous fungi DNA. The PCR 
mix for one reaction included 1x GoTaq Flexi buffer, 0.006 units/mL Taq polymerase, and 1.5 
mM MgCl2 (all from Promega Corporation, Madison, WI), 200 μM dNTP mix (BBI Biotech, 
Berlin, Germany) and 0.2 μM of the forward and reverse primers (MilliporeSigma, St. Louis, MO), 
10 μL of template, with MilliQ water up to 25 μL. The PCR protocol was denaturation at 95°C for 
5 min, amplification for 35 cycles of 94°C for 30 sec, 52°C for 30 sec, and 68°C for 30 sec, 
followed by a cooling down to 4°C. Four reactions per sample were performed. After reactions 
were pooled, the reactions were checked for purity on a 1% agarose gels for an amplicon size of 
250-600 bp and cleaned up using the Wizard SV Gel and PCR clean-up kit (Promega, Madison, 
WI). Purified DNA template was adjusted to 3-10 ng/μL using a NanoDrop ND1000 (NanoDrop 
Technologies, Wilmington, DE) for quantification and MilliQ water for dilutions. Reactions of 10 
μL DNA and 5 μL of 2 μM forward or primer were submitted to Robarts Research Institute 
(London, ON) for Sanger sequencing.  
 
Sequences were trimmed on both ends to exclude regions with significant no call bases, queried 
against the GenBank non-redundant nucleotide database using the National Center for 





Miller, Myers, & Lipman, 1990), and then species given the highest scoring matches were 
recorded. Partial ITS sequences returning the same highest-scoring species match were aligned 
using MUSCLE to look for sub-groups within the species. Higher-order taxonomic classification 
corresponding to subkingdom, phylum, subphylum, class, order, family were resolved using 
RStudio 3.6.2 and the taxize 0.9.92 package (Chamberlain & Szöcs, 2013) using genus names as 
queries and the taxonomy database from NCBI as a reference. 
 
2.5 Viable plate counts 
 
To estimate changes in viable soil fungal counts due to clotrimazole and miconazole exposure, 
soils were cultured on agar-solidified RB and DG18 media and the resulting number of colonies 
were counted (Table 1). The soil used for the plate counts was stored at 4℃ for less than 2.5 weeks 
after being sampled in November 2018 (Figure 5). For each plate, 100 μL of a 100 mg/mL soil 
slurry, corresponding to 10 mg of soil, was spread using a sterile plate spreader and incubated at 
4℃. Colonies were counted 1.5 weeks and 6 weeks post-incubation for the RB and DG18 plates, 
respectively. For a second plating set, soil slurries were prepared in duplicate for each plot from 
soils stored at 15℃ for three months after being sampled in April 2019 (Figure 6). As before, 10 
mg of each soil slurry was plated onto RB agar, but this time, incubated at 15℃ for four days. 
Plates that were overgrown or had large filamentous fungal colonies taking over half of a plate, 
which totalled two out of 24 plates, were excluded from plate counts. For plates containing large 
filamentous fungal colonies on one end of the plate, or for plates containing too many colonies 
overall, half-sections of the plates were counted. 
 
2.6 Ergosterol quantification for estimating biomass 
 
The soil samples used for ergosterol quantification were sampled in August 2018 and stored at 4℃ 
in the dark in tied, clear plastic bags. The samples were briefly removed from storage twice for 






Ergosterol quantification was performed by the AAFC technologist Lou Ann Verellen. Briefly, 5 
grams of soil, 3.5 grams of Ottawa Sand (Fisher Chemical, Ottawa ON), and 6 mL of methanol 
were combined in a 20 mL polyethylene scintillation vial, vortexed for 10 seconds and mixed using 
a wrist action shaker at room temperature for an hour. The mixture was then centrifuged for 10 
minutes at 3000 rpm in the Labofuge 6000 (Heraeus Christ, Osterode, Germany) and 1 mL of 
supernatant was filtered through a 0.2 mm polytetrafluoroethylene syringe filter and stored in a 
1.5 mL microcentrifuge tube. 
 
Following filtration, 20 μL of the supernatant was used for injection and ergosterol was measured 
using an Agilent 1260 Infinity high performance liquid chromatography system with a C-18 
reverse-phase column (Agilent Eclipse XDB-C18, 4.6mm x 100mm, 3.5μ). Parameters for the 
chromatography included a mobile phase of Acetonitrile:Methanol (70:30 v/v), a flow rate of 1.2 
mL/min, and temperature of 25 °C. Ergosterol was detected using an Agilent Diode Array detector 
at a wavelength of 282 nm.  
 
The retention time was 8.6 min as determined with an ergosterol standard (Sigma-Aldrich, St. 
Louis, MO). To produce the ergosterol standard curve, the ergosterol standard (10 mg/mL in 
chloroform) was measured at concentrations of 0.125, 0.25, 0.50, 0.75, 1.0, and 2.5 μg/mL. 
 
2.7 Assessing species richness within treatment groups 
 
To assess differences in species richness between control, low treatment, and high treatment plots, 
fungal isolates were identified and tallied by treatment type. For yeasts, isolates were clustered at 
the species level by sequencing while RAPD PCR and morphology were used to identify isolates 
without sequencing data. Seventeen out of 173 yeasts in the collection could not be classified at 
the time of writing. For filamentous fungi, only ITS sequencing was used to enumerate species as 
sequenced isolates with identical morphologies were shown to belong to different species and 








2.8 Antifungal susceptibility testing 
 
Drug stocks were prepared in 15 mL polypropylene conical tubes (Corning Inc., Corning, NY), by 
preparing stock solutions of 12.8 mg/mL clotrimazole (Sigma, St. Louis, MO), miconazole nitrate, 
fluconazole, itraconazole, difenoconazole, propiconazole and tebuconazole (all from AK 
Scientific, Union City, CA), and 6.4 mg/mL voriconazole (AK Scientific, Union City, CA). DMSO 
(Sigma, St. Louis, MO) was used a solvent for all drugs except for clotrimazole and tebuconazole, 
which were prepared in 95% ethanol (Commercial Alcohols, Toronto, ON). After allowing the 
drugs to dissolve in solution for at least two hours, the solutions were aliquoted into autoclaved 
1.5 mL Eppendorf tubes and either used immediately or stored at -80°C. Disks of Qualitative Type 
2 Whatman filter paper (Whatman, Maidstone, UK) were cut into disks 7 mm in diameter using a 
hole puncher and laid out onto sterile glass Pyrex petri dishes using sterile forceps. The Petri plates 
were then wrapped in aluminum foil, autoclaved on a dry setting of 121°C, 15 p.s.i. for 15 minutes 
and cooled to room temperature in a laminar flow hood before use. 
 
To prepare azole-containing filter paper disks, fluconazole stocks were diluted to 5 μg/μL, 
voriconazole stocks were diluted to 0.2 μg/μL, and all other drug stocks were diluted to 2 μg/μL 
in their appropriate solvent. Then, 5 μL of each drug were aliquoted onto the paper disks, while on 
the glass Pyrex Petri dishes, in a laminar flow hood, to produce 10 μg disks of clotrimazole, 
miconazole, itraconazole, tebuconazole, difenoconazole, and propiconazole, 20 μg disks of 
fluconazole, and 1 μg disks of voriconazole. The concentration of each medical azole disk was 
equal to the concentration of commercially prepared disks from Rosco Diagnostica (Rosco, 
Taastrup, Denmark), with the exception that the commercially prepared fluconazole disks are 25 
μg/disk.  Disks were dried in a laminar flow hood for a minimum of two hours after drug 
application to a maximum of overnight prior to use or storage. For storage, the Pyrex petri dishes 
containing the disks were placed in a metal canister with a desiccator, both previously dried and 
sterilized at 120°C in an oven but brought to room temperature in the flow hood, and then the 
canister was stored at -80°C. 
 
RPMI-glucose agar was prepared by combining 10.4 g RPMI powder (formulation 31800-089; 





(Biobasic Canada, Toronto, ON) with 800 mL ddH2O, microwaving until constituents were fully 
dissolved, and then autoclaving at 121°C, 15 p.s.i. for 15 minutes. Separately, 34.53 g of MOPS 
(Sigma, St. Louis, MO) and 0.15 g L-glutamine (Thermo Fisher Scientific, Waltham, MA) were 
combined in 200 mL ddH2O, sterilized through a 0.22 μm filter, and then added to the agarose 
mixture. After adjusting the pH of the agar to 7.0 using 6N NaOH, the agar was poured into plates 
5 mm thick. Mueller-Hinton agar (Becton, Dickinson and Company, Franklin Lakes, NJ), 
formulated to contain 20–25 mg/L calcium and 10–12.5 mg/L magnesium, was prepared per 
manufacturer’s direction and poured into agar plates with 5 mm of thickness. 
 
For testing yeasts, single colonies growing on SD agar at room temperature were suspended in 
Milli-Q water and adjusted to a turbidity of 0.07-0.11 absorbance at 590 nm in UVette® 
spectrophotometry tubes (Eppendorf AG, Hamburg, Germany). In most cases, colonies were 
grown for 48-60 hours, however, slow-growing colonies of Mrakia spp., Solicoccozyma terrea, 
and Filobasidium oeirense were grown on SD agar for up to one week. Susceptibility testing was 
performed by streaking the suspensions on RPMI–glucose agar using a sterile cotton swab and 
briefly drying the suspensions prior to disk application. For most isolates, clotrimazole, 
miconazole, itraconazole, voriconazole, and fluconazole disks were applied to one agar plate and 
difenoconazole, propiconazole, and tebuconazole were applied to a second agar plate. Plates were 
incubated at 30°C, or at 15°C if the maximum growth temperature was determined to be below 
30°C, typically, for 48 hours, and the zones of inhibition were measured from edge to edge using 
a ruler. Sensitivity assays of the slow-growing colonies of Solicoccozyma terrea and Filobasidium 
oeirense were incubated for 120 hours. Assays using Mrakia spp. were incubated for 96 hours, 
and assays including Vishniacozyma victoriae, Solicoccozyma aeria, Hannaella coprosmae and 
select isolates of Bullera alba and Sampaiozyma ingeniosa were incubated for 72 hours. Plates 
were also imaged on a flat surface using a levelled gel imager camera alongside an adjacent ruler 
for documentation purposes. 
 
For filamentous fungi, 10-100 μL of cryopreserved stock were pipetted onto three spots of a 0.2× 
PD agar plate and plates were incubated upright at room temperature for one to three weeks. Fungal 
biomass was obtained by gently swabbing colonies with a sterile cotton swab and suspending the 





biomass was not filtered to exclude all but conidia, large hyphal fragments were prevented from 
being introduced to the suspension by discarding fragments stuck to the end of the pipette tip. 
When possible, suspensions were adjusted to a turbidity of ABS590 = 0.07-0.11. Otherwise, initial 
fungal suspensions showing a turbidity below ABS590 = 0.07 were used as-is. Suspensions were 
spread with sterile cotton swabs onto MH agar, and Rosco Neo-Sensitabs™ (Rosco, Taastrup, 
Denmark) containing 10 μg clotrimazole or miconazole were placed onto the agar, and the plates 
were incubated at 25°C for 48-60 hours. Again, plates were imaged using the gel imager; however, 
unlike with the yeasts, measurements for zones of inhibition were measured from the images using 
the ruler as a guide. 
 
2.9 Quality control for antifungal susceptibility testing 
 
Selected yeasts were tested in duplicate to assess the impact of variation between sets of tests 
caused by variation in disk and plate properties, such as composition and dryness, inoculum 
preparation, such as density and colony freshness, and testing parameters, such as zone of 
inhibition measurements and incubation time. The largest variation was noted for an isolate of 
Schwanniomyces occidentalis showing a zone of inhibition to clotrimazole of 36 mm in one test 
and 44 mm in another test. Reproducibility also suffered in tests where isolates produced small 
zones of inhibition with extensive trailing growth towards a disk. For example, Rhodotorula 
isolates initially retested due to showing no zone of inhibitions when tested against miconazole 
and itraconazole, later showed zones of inhibition around 10 mm (Table 2). When multiple 
measurements of isolates were taken, the average zone of inhibition between trials was used in 
subsequent calculations. Filamentous fungi were tested using commercially prepared azole disks 
and yeasts tested against agricultural azoles were tested using limited batches of media, limiting 
batch variation. 
 
To test for reproducibility using different agars and disk preparation methods, two isolates of 
Rhodotorula mucilaginosa were tested in duplicate using paper disks on Mueller-Hinton agar and 
two isolates each of Cyberlindnera saturnus and R. mucilaginosa were tested on the standard 
RPMI-glucose agar with commercially-prepared 10 μg clotrimazole or miconazole Rosco 





definition around the miconazole and itraconazole disks than RPMI-glucose agar, possibly due to 
the lack of a dye in the former. Still, the zones of inhibition to clotrimazole were within error range 
to those on RPMI-glucose agar. In addition, although the Neosensitab disks were significantly 
larger at 10 mm in diameter versus 7 mm in diameter for the filter paper disks, the susceptibility 
and resistance phenotypes were identical using the different disks for the C. saturnus and R. 
mucilaginosa isolates. 
 
To confirm that zones of inhibition were caused by the drug impregnated into the disk and not the 
solvent carrier, preliminary experiments were undertaken with disks containing only the ethanol 
or DMSO solvents. In no instances did either solvent inhibit the growth of 25 yeasts (18 C. 
saturnus, three R. mucilaginosa, two Debaryomyces hansenii, and two Bullera alba) or 25 
filamentous fungi of various species tested. 
 
Table 2 – Average ZOI (mm ± Standard Deviation) of Yeasts Tested using Different Batches 
of Media 
To check for variation in zones of inhibition measurements with sensitivity testing of yeasts, select 
yeasts were tested using different batches of media. Isolate A was identified as Schwanniomyces 
occidentalis and tested against three batches of media while other isolates were tested against two 
different batches and isolates B and C were identified as Rhodotorula mucilaginosa, isolates D 
and E were Cyberlindnera saturnus, isolate F was Bullera alba, and isolate G was 
Cutaneotrichosporon terricola. R = resistant phenotype, n.d. = not tested in duplicate. 
 Clotrimazole Miconazole Fluconazole Voriconazole Itraconazole 
Isolate A 40.0 ± 3.3 26.7 ± 2.1 29.0 ± 1.0 35.3 ± 3.3 25.3 ± 0.9 
Isolate B 27.5 ± 0.5 10.0/R R/R R/R 11.0/R 
Isolate C 29.0 ± 0 R/R R/R R/R 11.1/R 
Isolate D 24.0 ± 0 19.5 ± 0.5 R/R 18.5 ± 1.5 14.0 ± 0 
Isolate E 22.5 ± 1.5 20.0 ± 0 R/R 19.0 ± 1.0 14.0 ± 0 
Isolate F 35.5 ± 0.5 R/R R/R R/R 23.0 ± 2 








2.10 Determining levels of susceptibility or resistance to 
drugs 
 
For tested yeasts, the majority of susceptibility tests to the eight azole drugs either produced large, 
clearly-defined zones of inhibition, indicating that an isolate was susceptible to the drug, or no 
zone of inhibition surrounding the drug disks, indicating resistance. However, several isolates 
tested against particular drug disks showed extensive ‘trailing growth’ indicative of a fungistatic 
drug effect. These isolates produced microcolonies directly surrounding the drug disk with colony 
size increasing in size with increasing distance to the disk. In these cases, zones of inhibition were 
measured from edge-to-edge using normal-sized colonies, as determined by colonies growing in 
the absence of drug, as endpoints. Examples of tests returning results and their classification can 
be found in the Appendix (Supplementary Figure 1). 
 
 
2.11 Statistical analysis 
 
To determine if resistance to one azole drug was associated with resistance to another azole drug, 
pair-wise comparisons were performed. Contingency tables comparing the number of isolates 
determined to be resistant or susceptible to each drug were constructed as shown in the Appendix 
(Tables 3 and 4). Fisher Exact tests were performed using an on-line calculator (Stangroom, 2020) 
with a significance level of 0.05.  
 
In addition, to estimate the relationship between susceptibility to one drug versus another drug, 
linear regression analysis across all isolates was performed using the zones of inhibition to the two 
drugs to the same isolate as variables. 
 
Any potential treatment effect on the sensitivity of recovered fungi to the azole drugs by soil 
treatment origin was determined using a two-tailed T-test for two independent means and 
calculated using an online calculator and a significance level of 0.05 (Stangroom, 2020b). Data 





indicated that the tested isolate was resistant to the tested drug, were represented in the dataset 









3.1 Impact of azole exposure on culturable fungal propagules 
 
The azole concentrations in the treated soils steadily increased with annual azole application to an 
average, with noted standard deviation between the four treatment plots, of 0.22 ± 0.09 mg/kg of 
miconazole and 0.13 ± 0.04 mg/kg of clotrimazole in the low treatment soils and 19.58 ± 3.77 




Figure 7 – Concentration of Azoles in the Low and High Treatment Plots Over Time  
Average concentration of the drugs in the four low and four high treatment plots collected prior 
to annual drug application is shown with the error bars showing standard deviation in azole 



































































































The impact of long term fungicide exposure on viable populations of filamentous fungi and yeasts 
was evaluated by viable plate counts on RB and DG agar using soils sampled in 2018 following 
nine annual drug applications. Statistical tests performed using a two-tailed T-test for two 
independent means (Stangroom, 2020b) using the plate count data found higher colony numbers 
on plates plotted with control soil than plates plotted with high treatment soil on RB agar (p≤0.01 
for incubations at both 4℃ and 15℃) but this difference was not seen on the DG agar incubated 
at 4℃ (p=0.32) (Figure 8).  
 
 
Figure 8 – Plate Counts from Soils Receiving No, Low, or High Azole Treatments 
Plate counts show reduced fungal load in high treatment plots compared to control plots on RB 
agar bur not DG agar. An outlier plate from the control plot #26 soil with 260 CFU/g soil and an 
outlier plate from the high treatment soil with 1,800 CFU/g soil were excluded from the RB agar 
incubated at 15℃ bar chart; however, even with these outliers p=0.01 between the control and 
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In addition, to estimate fungal biomass, ergosterol in extracts of soil in August of 2018 was 
quantified by high performance liquid chromatography (Figure 9). The ergosterol concentration in 
the high treatment versus control soils was significantly lower in the soils. 
 
Figure 9 – Ergosterol Content in Control versus Azole-treated Soils 
Ergosterol decreased in the high treatment plots receiving annual applications of azoles versus 
untreated control plots after eight years of annual azole application.  
 
3.2 Fungal cultivation and isolation 
 
Soil from each of the 12 plots were plated onto 0.2× strength SD and 0.2× PD agar amended with 
1 mg/L miconazole and 1 mg/L clotrimazole in DMSO (Figure 4). For the 0.2× SD agar plates, 
one of four plates inoculated with control soil yielded bacterial growth, and of the four plates 
inoculated with high treatment soil, one showed bacterial growth, and another showed filamentous 
fungi growth. No growth was observed on any other plate after eight days. On 0.2× PD agar, 




















































containing low treatment soils, and none of the four plates containing control soils (Figure 10). 
Organisms from these plates were not retained in the collection. 
 
  
Figure 10 – Observations from Azole-treated Soils Plated on Antifungal-containing Media 
Growth was observed on 0.2-strength potato dextrose plates containing clotrimazole and 
miconazole when plated with the high treatment soils but not the control soils. None of the plates 
plated with the four control soils produced growth (A), but all of the plates plotted with high 
treatment soil produced growth (B). 
 
Overall, 42 yeasts were obtained from soils sampled in August 2018. All obtained isolates from 
the plating on DBDM agar matched to Cyberlindnera saturnus and all but two of thirty isolates 
obtained on the 0.2× strength media containing C-TAB corresponded to C. saturnus, Rhodotorula 
mucilaginosa, or Bullera alba.  
 
Seventy-three yeasts were isolated from the October 2018 soils. C. saturnus was the only species 
isolated on the CZ agar, and was the predominant species isolated from the YM-11 agar, along 
with R. mucilaginosa, and the ME agar, along with R. mucilaginosa and Debaryomyces spp. The 
yeasts from the 4℃ incubations were more diverse with, among 15 isolates from each set, 11 
species from the RB agar and more than eight species from the DG agar. Anaerobic incubation 
yielded few yeasts, five among two sets of SD and RB agar plates, with isolates belonging to 
Sampaiozyma ingeniosa (n=2), Hannaella coprosmae, D. hansenii, and R. mucilaginosa. In 
addition, fifty-five filamentous fungi that were used for sensitivity testing were isolated from the 
October 2018 soils. Mucor and Clonostachys species were the predominant isolates from the RB 








From the soils sampled in April 2019, forty-two yeasts from more than nine species were obtained 
from the enrichment in MH broth and incubation on MH agar. The high efficiency of this isolation 
may be attributed to the fact that the soils were put into enrichment within days of being sampled 
from the field with a 15℃ storage in the interim. In addition, forty-five filamentous fungi used for 
sensitivity testing were obtained from the soils. Of note, the isolates from the incubation on GYP 
at 15℃ were dominated by Mucor and Mortierella species while the MH incubation at 50℃ 
showed growth of the pathogen Aspergillus fumigatus. 
 
3.3 Identification of fungal isolates 
 
Of the 173 yeasts isolated prior to February 2020, 81 were identified by ITS sequencing, 43 were 
identified by a combination of RAPD PCR and morphology and 46 were preliminarily identified 
by morphology only. Paired-end sequencing of 26 amplicons produced an identical overlapping 
sequence that could be used for identification so single-end sequencing was used 
thereafter.  Sequenced isolates from the yeast collection yielded 31 unique ITS sequences 
representing 28 species (Table 3). Four isolates gave less than 99% ID to any isolate given by 
NCBI BLAST and one isolate did not have any close matches to any other classified organism in 
the database.  
 
For initial identification, all yeasts were streaked onto 1× SDA and checked after at least one week 
of growth at room temperature. C. saturnus was distinguished by white colonies showing a raised 
centre surrounded by web-like growth while D. hansenii was distinguished by flat, white colonies 
and B. alba showed small, beige colonies. Meanwhile, Rhodotorula showed pink-red, smooth, 
sometimes mucoid, colonies and Wang et al. (2015) was used as a guide to distinguish 
Rhodotorula from similarly pigmented yeasts.  
 
Following grouping by morphology, RAPD PCR using genomic DNA from 88 yeasts was used to 








Figure 11 – Representative RAPD PCR Gel for Identification of Cyberlindnera saturnus 
PCR fingerprints highlighted in green were identified by ITS sequencing as Cyberlindnera 
saturnus and all other isolates were assumed to be Cyberlindnera saturnus due to similar 
fingerprints and morphology. 
 
Yeasts showing unique morphologies or RAPD PCR fingerprints in addition to representative 
isolates from yeasts with identical morphologies and RAPD PCR fingerprints were sequenced. 
Overall, by morphology only, 11 isolates were assigned to Cyberlindnera saturnus, 12 isolates to 
Rhodotorula, three isolates to Debaryomyces, and one isolate to Bullera alba. An additional 30 
isolates were identified as C. saturnus, 10 isolates were identified as R. mucilaginosa, and three 
isolates were identified as D. hansenii using a combination of morphology and by sequencing a 
representative of a PCR fingerprint. 
For filamentous fungi, suspensions of filamentous fungal colonies were aliquoted onto 0.2× PDA 
and 1× MH agar in triplicate. Colonies were imaged following adequate growth. By morphology, 
four isolates were identified as Mucor spp., three isolates each as Cladosporium spp., Clonostachys 
spp., and Mortierella spp., and two isolates as Aspergillus species. 
In addition, partial ITS sequencing was performed on 73 filamentous fungal isolates from the 
collection, yielding 27 unique ITS sequences representing 22 species (Table 4). 
 
While species-level resolution was obtained for most isolates, the sequencing could not distinguish 
between the members of certain species-complexes, such as the Fusarium incarnatum-equiseti and 
Cladosporium cladosporioides species complexes, as well as Aspergillus wentii and closely related 





Table 3 – Community Composition of Yeasts Isolated from the Soils.  
Isolate counts were primarily identified by ITS sequencing, with sequences provided in Supplementary Table 1.0., with counts of isolates 
preliminarily identified by morphology or RAPD PCR noted by parentheses. A single yeast isolate from the high treatment plot, noted 
as ‘Isolate FK01_169’, showed no significant match in the NCBI database even when using pair-ended sequencing.  
 
Phylogenetic Data of Isolate Count by Plot Origin 
Phylum Class Order Family Genus Species Control Low High 
Basidiomycota Tremellomycetes Tremellales Bulleraceae Bullera alba 2 (1) 3 3 
Basidiomycota Tremellomycetes Trichosporonales Trichosporonaceae Cutaneotrichosporon terricola 1    
Ascomycota Saccharomycetes Saccharomycetales Phaffomycetaceae Cyberlindnera saturnus 2 (12) 4 (22) 5 (7) 
Basidiomycota Tremellomycetes Cystofilobasidiales Cystofilobasidiaceae Cystofilobasidium infirmominiatum 2 2   
Basidiomycota Tremellomycetes Cystofilobasidiales Cystofilobasidiaceae Cystofilobasidium capitatum  1   




1 (2) 1 (1) 2 (3) 




1    
Ascomycota Saccharomycetes Saccharomycetales Saccharomycetales Diutina catenulata 1    
Basidiomycota Tremellomycetes Filobasidiales Filobasidiaceae Filobasidium oeirense  1   
Basidiomycota Tremellomycetes Filobasidiales Filobasidiaceae Goffeauzyma gastrica 1    
Basidiomycota Tremellomycetes Tremellales Bulleribasidiaceae Hannaella coprosmae 1    
Basidiomycota Tremellomycetes Tremellales Bulleribasidiaceae Hannaella oryzae (A) 1    
Basidiomycota Tremellomycetes Tremellales Bulleribasidiaceae Hannaella oryzae (B) 1    
Basidiomycota Microbotryomycetes Leucosporidiales Leucosporidiaceae Leucosporidium 
creatinivorum, 
yakuticum, scottii 
1 1   
Basidiomycota Tremellomycetes Cystofilobasidiales Mrakiaceae Mrakia arctica, gelida  3   
Basidiomycota Tremellomycetes Cystofilobasidiales Mrakiaceae Mrakia blollopis 2    












NA NA NA NA NA FK01_169   1 
Basidiomycota Tremellomycetes Tremellales Rhynchogastremataceae Papiliotrema flavescens  1   
Basidiomycota Microbotryomycetes Sporidiobolales Sporidiobolaceae Rhodotorula mucilaginosa 8 (5) 4 (7) 8 (11) 
Basidiomycota Microbotryomycetes Sporidiobolales Sporidiobolaceae Rhodotorula graminis 3 1   
Basidiomycota Microbotryomycetes Sporidiobolales Sporidiobolaceae Rhodotorula babjevae 1    
Basidiomycota Microbotryomycetes Microbotryomycetes Chrysozymaceae Sampaiozyma ingeniosa 2 2 3 
Ascomycota Saccharomycetes Saccharomycetales Debaryomycetaceae Schwanniomyces occidentalis  1   
Basidiomycota Tremellomycetes Filobasidiales Piskurozymaceae Solicoccozyma terrea   1 
Basidiomycota Tremellomycetes Filobasidiales Piskurozymaceae Solicoccozyma aeria  1   
Basidiomycota Tremellomycetes Cystofilobasidiales Mrakiaceae Tausonia pullulans (A) 1 1 1 
Basidiomycota Tremellomycetes Cystofilobasidiales Mrakiaceae Tausonia pullulans (B)   1 
Basidiomycota Tremellomycetes Tremellales Bulleribasidiaceae Vishniacozyma sp. isolate C220   1 
Basidiomycota Tremellomycetes Tremellales Bulleribasidiaceae Vishniacozyma 
heimaeyensis, 
foliicola 
  1 





Table 4 – Community Composition of Filamentous Fungi Isolated from Soils. Sequences are provided in Supplementary Table 2. 
Phylogenetic Data of Isolate Count by Plot Origin 
Phylum Class Order Family Genus Species Control Low High 
Ascomycota Leotiomycetes Leotiomycetes Leotiomycetes Acremonium sp. MJ35   1 
Ascomycota Sordariomycetes Sordariales Chaetomiaceae Acrophialophora levis 1 2  
 Mucoromycetes Mucorales Mucoraceae Actinomucor elegans (A) 3 1  
 Mucoromycetes Mucorales Mucoraceae Actinomucor elegans (B) 1   
Ascomycota Sordariomycetes Hypocreales Stachybotryaceae Albifimbria 
verrucaria, 
viridis 
1   
Ascomycota Eurotiomycetes Eurotiales Aspergillaceae Aspergillus 
fumigatus, 
fumigatiaffinis 
1 1 1 
Ascomycota Eurotiomycetes Eurotiales Aspergillaceae Aspergillus [multiple] 1   
Ascomycota Dothideomycetes Capnodiales Cladosporiaceae Cladosporium [multiple]  2  
Ascomycota Sordariomycetes Hypocreales Bionectriaceae Clonostachys rosea (A) 4 8 5 
Ascomycota Sordariomycetes Hypocreales Bionectriaceae Clonostachys rosea (B)  1 1 
Ascomycota Sordariomycetes Hypocreales Nectriaceae Fusarium oxysporium 3 1 1 
Ascomycota Sordariomycetes Hypocreales Nectriaceae Fusarium 
incarnatum-
equiseti 
1 1  
Ascomycota Sordariomycetes Hypocreales Clavicipitaceae Metarhizium robertsii 1 1  
Ascomycota Sordariomycetes Hypocreales Clavicipitaceae Metarhizium marquandii 1 1  
 Mucoromycetes Mucorales Mucoraceae Mortierella alpina (A)  2 1 
 Mucoromycetes Mucorales Mucoraceae Mortierella alpina (B)   1 
 Mucoromycetes Mucorales Mucoraceae Mortierella alpina (C)  1  
 Mucoromycetes Mucorales Mucoraceae Mortierella gamsii  1  







 Mucoromycetes Mucorales Mucoraceae Mucor circinelloides 1  1 
Ascomycota Eurotiomycetes Eurotiales Aspergillaceae Neosartorya udagawae 1   
Ascomycota Eurotiomycetes Eurotiales Aspergillaceae Penicillium oxalicum (A) 1  2 
Ascomycota Eurotiomycetes Eurotiales Aspergillaceae Penicillium oxalicum (B) 1   
Ascomycota Eurotiomycetes Eurotiales Aspergillaceae Penicillium 
novae-
zeelandiae 
1   
Ascomycota Sordariomycetes Glomerellales Plectosphaerellaceae Plectosphaerella cucumerina  1  
Ascomycota Sordariomycetes Hypocreales Ophiocordycipitaceae Purpureocillium lilacinum  2  





3.4 Fungal population structure analysis 
 
When looking at yeasts, the collection from the control plots have notably more species than those 
from the high treatment plots. Of 34 sequenced yeasts isolates from the control plots and 27 isolates 
each from the low treatment and high treatment plots, 18 (52% of identified isolates), 15 (55%), 
and 10 unique species (37%) were observed (Table 3), respectively. On the other hand, for 
filamentous fungi, 17 species of 26 identified isolates (65%), 17 species of 31 isolates (55%), and 
10 species of 17 (59%) isolates were observed from the control, low, and high treatment plots, 
respectively (Table 4). Although the yeast collection from the high treatment plots has a notably 
lower species richness than the yeast collection from the control plots, a similar effect was not seen 
with filamentous fungi, possibly due to under-sampling of the filamentous fungi community. 
 
3.5 Sensitivity of isolates to drugs 
 
With respect to the medical imidazoles, clotrimazole and miconazole, of 138 tested yeasts to each 
drug, 93.5% and 86.2% of isolates were determined to be sensitive to clotrimazole and miconazole, 
respectively.  Of the sensitive isolates, 3.9%, were determined to be only weakly susceptible to 
clotrimazole but notably more, 16.8%, were weakly susceptible to miconazole (Figure 12). 
 
In contrast to the medical imidazoles and agricultural triazoles, the percentage of sensitive isolates 
to the medical triazoles fluconazole and voriconazole was significantly lower. Of 119 tested 
isolates, only 14.3% and 58.9% of isolates showed sensitivity to fluconazole and voriconazole, 
respectively. On the other hand, most isolates, 94.1% of 119 isolates, were sensitive to 
itraconazole. The percent of weakly susceptible isolates was relatively high with 17.6%, 11.4%, 
and 12.5% of susceptible isolates to fluconazole, voriconazole, and itraconazole, respectively, 
being defined as weakly susceptible (Figure 12). 
 
With respect to the agricultural triazoles, 100% of 104 and 98 isolates tested against 





standard assay. Meanwhile, 93.3% of 104 isolates tested against propiconazole showed a sensitive 





Figure 12 – Distribution of Susceptibilities of Yeasts Tested against Various Azoles 
Sensitivity of yeasts isolated from all soils tested against eight azole drugs show that the tested yeasts were most susceptible to the tested 
agricultural triazoles difenoconazole, propiconazole, and tebuconazole, followed by the medical imidazoles clotrimazole, miconazole, 
and then the medical triazoles voriconazole, itraconazole, and fluconazole. Susceptibility of isolates to the drugs were ranked by diameter 
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3.6 Cross-resistance between drugs against yeasts 
 
Overall, resistance to voriconazole was associated with resistance to all other medical drugs and 
propiconazole (p<0.001 for each pair-wise comparison) (Supplementary Table 3.1-3.5). Also, 
resistance to itraconazole was correlated with resistance to fluconazole (p=0.002; Supplementary 
Table 3.6) and resistance to either was significantly correlated with resistance to miconazole 
(Supplementary Table 3.7- 3.8). However, resistance to clotrimazole was not associated with 
resistance to miconazole (p=0.107; Supplementary Table 3.9), fluconazole (p=0.050; 
Supplementary Table 3.10), or itraconazole (p=0.123; Supplementary Table 3.11). As for the 
agricultural triazoles, resistance to propiconazole was associated with resistance to the medical 
imidazoles, clotrimazole (p<0.001; Supplementary Table 3.12) and miconazole (p<0.001; 
Supplementary Table 3.13), in addition to voriconazole, but not to itraconazole (p=0.479; 
Supplementary Table 3.14) or fluconazole (p=1; Supplementary Table 3.15). Analyses of cross-
resistance could not be made for difenoconazole and tebuconazole toward the other drugs as all 
isolates tested against these two drugs were susceptible. 
 
Cross-resistance to multiple drugs was often associated with particular species. Strains of Bullera 
alba were frequently multi-drug resistant with two out of nine tested strains being resistant to 
clotrimazole, miconazole, voriconazole, fluconazole, and propiconazole and an additional strain 
being sensitive to all of the above drugs except clotrimazole. In addition, all tested Rhodotorula 
mucilaginosa isolates were resistant to fluconazole, with the majority of isolates also being 
resistant to voriconazole, and four out of 41 strains showing complete resistance to miconazole 
and itraconazole as well. In addition, five out of six Sampaiozyma ingeniosa strains were resistant 
to miconazole, voriconazole and fluconazole.  
 
Regression analysis did not indicate that the extent of sensitivity, as measured by the size of the 
zone of inhibition, for a given isolate to any azole was directly correlated with the sensitivity to 





Table 5 – Regression Analysis using ZOI (mm) of the Same Isolate Tested Against Two Drugs as Variables. R2 values shown. 
 
 
Clotrimazole Miconazole Voriconazole Itraconazole Fluconazole Difenoconazole Propiconazole 
Miconazole 0.00       
Voriconazole 0.01 0.46      
Itraconazole 0.01 0.37 0.35     
Fluconazole 0.01 0.19 0.51 0.16    
Difenoconazole 0.41 0.06 0.22 0.03 0.38   
Propiconazole 0.05 0.45 0.35 0.12 0.21 0.01  
Tebuconazole 0.22 0.10 0.15 0.02 0.20 0.50 0.09 
 
 
Table 6 – Mean ZOI (mm ± standard deviation) of Isolates Tested Against Azoles by Plot Type Origin. 
 
 Clotrimazole Miconazole Voriconazole Itraconazole Fluconazole Difenoconazole Propiconazole Tebuconazole 
Yeasts         
Control 23.5 ± 10.7 14.3 ± 7.3 8.5 ± 12.4 14.8 ± 7.1 66.0 ± 10.8 42.4 ± 9.9 27.3 ± 10.9 31.6 ± 6.3 
Low treatment 22.8 ± 7.8 14.4 ± 6.3 12.7 ± 10.2 14.4 ± 5.5 81.0 ± 8.3 34.3 ± 9.5 28.5 ± 9.1 30.2 ± 7.4 
High treatment 21.9 ± 11.8 11.7 ± 8.0 90.0 ± 11.3 12.0 ± 6.3 44.0 ± 7.1 38.7 ± 9.1 25.9 ± 11.5 32.6 ± 2.6 
 
Filamentous fungi         
Control 22.2 ± 8.8 17.5 ± 11.6       
Low treatment 25.2 ± 11.6 17.2 ± 11.9       





3.7 Susceptibility patterns of isolates to medical imidazoles 
 
The susceptibility of isolates obtained from control and treated soils toward clotrimazole and 
miconazole were not found to be different. The average zone of inhibition (ZOI), with sample-
based standard deviation to clotrimazole was 23.5 ± 10.7 mm, 22.8 ± 7.8 mm, and 21.9 ± 11.8 mm 
when testing yeasts from the control (n=50), low (n=53), and high treatment (n=43) plots, 
respectively (Table 6). The average ZOI when testing 33 filamentous fungi from the control plots, 
31 isolates from the low treatment plots, and 24 isolates from the high treatment plots was 22.2 ± 
8.8 mm, 25.2 ± 11.6 mm, and 21.9 ± 2.9 mm, respectively (Table 6). In both cases, As shown by 
a two-tailed T-test for two independent means, there was no significant difference in average zone 
of inhibition between tests using isolates from the control versus low treatment plots (p=0.68 for 
yeasts, p=0.23 for filamentous fungi) or between the control versus high treatment plots (p=0.43 
for yeasts, p=0.88 for filamentous fungi). Likewise, the average ZOI using miconazole disks and 
yeasts from the control, low, and high treatment plots showed no difference in susceptibilities 
between yeasts from the control plot versus the low treatment plots (p=0.92), or versus the high 
treatment plots (p=0.12) (Table 6). Similarly, with respect to all tested filamentous fungi, the 
average ZOI using control versus low treatment-origin isolates was not statistically significant 
(p=0.19), nor was the difference when testing control versus high treatment-origin yeasts (p=0.17) 
(Table 6). 
 
The sensitivities of isolates from within a given species were tested to clotrimazole and miconazole 
to compare the degree of variation from isolates originating from the control plots with isolates 
originating from the treated plots. On a species-level, zones of inhibition were very similar when 
testing 53 Cyberlindnera saturnus isolates against clotrimazole and miconazole, with average ZOI 
not being statistically significantly different when testing isolates from the control versus low 
treatments (p=0.90) and control and high treatments (p=0.63) (Figure 13). A similar lack of 
treatment effect was seen with 17 Clonostachys rosea isolates and 10 Rhizomucor variabilis 
isolates tested against the medical imidazoles (Figure 13). 
 
Although Rhodotorula isolates from the control treatment appeared to be more resistant to 





± 2.7 mm when testing the control-origin isolates versus 37.2 ± 2.6 mm when testing the high 
treatment-origin isolates (p=0.006), there was no statistically significant difference in average ZOI 
when testing control versus low-treatment origin isolates (p=0.11) at 34.2 ± 2.7 mm versus 36.1 ± 
3.1 mm (Figure 13).  
 
To further test Rhodotorula isolates against clotrimazole, two additional tests were performed. 
Isolates were grown on SD agar plates at room temperature and then sub-cultured on MH agar and 
incubated for approximately 12 hours at 30℃. Following growth, a 10 μL loop of cells was used 
for susceptibility testing using RPMI-glucose agar and Neosensitab disks. Susceptibility tests were 
then performed except seven isolates each from the control and high treatment plots were incubated 
with reduced oxygen by incubation in a large BD GasPak EZ container (Becton, Dickinson and 
Company, Franklin Lakes, NJ) containing one Mitsubishi AnaeroPouch-MicroAero pouch 
(Mitsubishi Chemical Holdings, Tokyo, Japan), and 17 isolates from the control plots and 11 
isolate from the high treatment plots were incubated under standard conditions for seven days. 
Although two MicroAero pouches are needed to create the standard microaerophilic environment 
in a large GasPak EZ container, a Mitsubishi Anaero-Indicator indicated reduced oxygen 
concentration within the container throughout the incubation period of 48 hours. In both cases, 
Rhodotorula isolates from the high treatment plots were not any more or less susceptible to 
clotrimazole then those from the control plots (p=0.18 for the reduced oxygen incubation, and 
p=0.37 for the seven-day incubation). Interestingly, in both cases this time, isolates from the 
control plots appeared to be more susceptible to the clotrimazole than those from the high treatment 
plots with average zones of inhibition of 37.0 ± 2.1 mm versus 34.7 ± 3.6 for the reduced oxygen 
trial and 34.2 ± 2.4 versus 33.1 ± 4.6 mm for the seven-day incubation. Overall, given the increased 
testing, it appears that the initial results of Rhodotorula isolates from the high treatment being 
more susceptible to clotrimazole than isolates from the control was due to a sampling error. 
 
3.8 Isolates highly susceptible to medical imidazoles 
 
Eleven yeasts, representing 7.6% of the collection, were considered to be highly susceptible to 
miconazole due to ZOI measurements being greater than or equal to 25.0 mm (Figure 12). These 





azole fungicides. The isolates represented 17% of tested isolates from the control plots (n=8 of 47) 
and were identified as Bullera alba, Cutaneotrichosporon terricola, Diutina catenulata, 
Hannaella oryzae (n=2), Mrakia arctica, Sampaiozyma ingeniosa, and Vishniacozyma victoriae, 
3.8% of isolates from the low treatment plots (n=2 of 53) and included Schwanniomyces 
occidentalis and Solicoccozyma aeria, and 4.5% of tested isolates from the high treatment plots 
(n=2 of 44) which included a Bullera alba isolate and an unidentified psychrophilic isolate. As 
calculated by a Fisher exact T-test, the proportion of isolates highly susceptible to miconazole was 
statistically significant between the control and low treatment plots (p=0.04; Supplementary Table 
4.1) but not between the control and high treatment plots (p=0.09; Supplementary Table 4.2). 
 
On the other hand, when defining yeasts highly sensitive to clotrimazole as having a ZOI ≥ 300 
mm in diameter (n=51) in the disk diffusion assays, 46%, 26%, and 32% of control, low treatment, 
and high treatment-origin isolates were defined as highly susceptible. Increasing the threshold for 
high susceptibility to a ZOI ≥ 350 mm included 30 isolates from all plots and led to 24%, 17%, 
and 20% of the control, low treatment, and high treatment collections falling under the definition. 













Figure 13 – Sensitivities of Selected Species to Clotrimazole and Miconazole 
Sensitivity assays with select yeasts and filamentous fungi species against 10 μg clotrimazole disks 
shows a significant difference in zones of inhibition when testing R. mucilaginosa isolates from 
the control versus high treatment plots. No other statistically significant pair-wise difference was 
detected. Likewise, sensitivity assays with selected yeasts and filamentous fungi species against 
10 μg miconazole disks showed no differences in average zones of inhibition based on soil type 






















































































































3.9 Susceptibility patterns of isolates to medical triazoles 
 
Of 146 yeasts tested against itraconazole, the average ZOI using isolates from the control plots 
versus the high treatment plots was slightly higher at 14.8 ± 7.1 versus 12.0 ± 6.3 mm (p=0.06). 
Nonetheless, C. saturnus, R. mucilaginosa, and D. hansenii isolates from the control versus high 
treatment plots were not significantly more or less sensitive to itraconazole (p=0.35, p=0.46, and 
p=0.44, respectively) (Figure 14). Similarly, among 96 tested yeasts against voriconazole, there 
was no significant difference in average ZOI when testing isolates from the control versus low 
treatment plots (p=0.37) or high treatment plots (p=0.13) to the disks. Likewise, no difference in 
average ZOI to voriconazole was found when testing C. saturnus isolates from the control versus 
the low treatment plots (p=0.88) or versus the high treatment plot (p=0.17) (Figure 14). Only 25 
of 158 tested yeasts were susceptible to fluconazole but, overall, no significant difference was 
found in average ZOI when testing isolates from the control versus treated plots.  
 
3.10 Susceptibility patterns of isolates to agricultural triazoles 
 
Similar to the medical imidazoles and medical triazoles, for the agricultural triazoles, in general, 
no statistically significant differences were found between the average zones of inhibition for 
isolates from the control plots (n=38 to 39 for each drug) versus the low treatment plots (n=38 for 
difenoconazole and propiconazole, n=30 for tebuconazole), or for the control versus the high 
treatment plots (n=34 for difenoconazole and propiconazole, n=30 for tebuconazole). For isolates 
tested against the propiconazole disks, the average zones of inhibition was 27.3 ± 109 mm, 28.5 ± 
91 mm, 25.9 ± 11.5 mm for control, low treatment, and high treatment-origin isolates, respectively 
and for isolates tested against tebuconazole, the averages were 31.6 ± 6.3 mm, 30.2 ± 7.4 mm, and 
32.6 ± 6.2 mm, respectively (Table 6). However, isolates from the low treatment plot appeared to 
be significantly more resistant to difenoconazole than those from the control treatment plots 
(p=0.0004) with an average zone of inhibition of 34.3 ± 9.5 mm for isolates from the low treatment 
plot versus 42.4 ± 9.9 mm for the isolates from the control plots (Table 6). When the average zone 
of inhibition from the control plot isolates was compared to that of the high treatment isolates, 38.7 





inhibition toward the three agricultural azoles for the yeast Cyberlindnera saturnus, Rhodotorula 
mucilaginosa, and Debaryomyces spp. showed little variation per species per drug, as typical for 
the clinical azoles, large variation in particular was seen within Bullera alba isolates toward 
difenoconazole. Isolates of B. alba from the control (n=3), low treatment (n=3), and high treatment 
(n=3) plots produced average zones of inhibition to difenoconazole at 43.0 ± 4.6 mm, 33.7 ± 15.5 
mm, and 29.3 ± 6.0 mm, respectively. 
 
 
Figure 14 – Sensitivity of Cyberlindnera saturnus Isolates to Triazoles 

























































4.1 Impact of fungicide exposure on population dynamics 
 
As shown by the plate counts on RB agar, the lower number of recovered colonies per gram of soil 
plated between the soils from the control versus the high treatment suggests that the clotrimazole 
and miconazole in the high treatment plots led to lower viable fungal propagules (Figure 8). The 
fact that the high treatment soils sampled in 2018 had lower ergosterol content per gram of soil 
than the samples from the control plots further shows that the high treatment soils have reduced 
fungal load due to the long-term effects of the antifungal drugs in the soil (Figure 9). The increase 
in ergosterol content seen in the control soils versus the high treatment soils sampled in 2018 may 
have been due to increased fungal growth in the rhizosphere of the cropped soybeans over eight 
years (Figure 9). 
 
The RB and DG agars contain rose bengal and dichloran, respectively, which inhibit the radial 
growth of fungi that can spread over large portions of the plate in a species-dependent manner 
(King et al., 1979). This leads to higher colony counts and the effective isolation of slower-
growing species (Henson, 1981; Hocking & Pitt, 1980; King et al., 1979). In addition, incubation 
at 4℃ selects for yeasts, especially psychrophilic yeasts, over filamentous fungi, and the addition 
of 220 g/L glycerol in the DG agar selects for xerophilic species. One possible reason why the 
colony counts on DG agar did not show a significant difference between treated and untreated soils 
is due to the sporulation of filamentous fungi after the six week incubation period. Nonetheless, 
the RB plates incubated at 15℃ for four days were almost exclusively dominated by filamentous 
fungi growth while still showing significant differences in colony counts between the control 
versus high treatment soils. 
 
The observation that both the yeasts and filamentous fungi collections from the control plots 
showed lower diversity in the control plots versus the treated plots can be attributed to the fact that 
several species were isolated only from the control plots but not the treated plots. Several yeasts, 





(Table 2). Half of these unique isolates were isolated from the control plots while the remaining 
half were isolated evenly between the low treatment and high treatment plots. In addition, 
five Mrakia spp., and four isolates each of Cystofilobasidium infirmominiatum and Rhodotorula 
graminis were isolated from the control and low treatment plots, but not the high treatment plots. 
Likewise, for the filamentous fungi collection, 16.4% of identified isolates (12 of 73 isolates) 
belonged to species represented only once in the dataset with half of these species being isolated 
from the control plots (Table 3). 
 
For the yeast collections from the control plots and high treatment plots, 
respectively, Cyberlindnera saturnus comprised 20% and 27% of the collections 
while Rhodotorula mucilaginosa comprised 32% and 25%. However, it should be noted that the 
fungal collections were constructed with the goals of maximizing diversity in the collections and 
minimizing clonality. In particular, when broths enriched for yeasts were plated onto agar, if 
colonies with identical morphologies were observed on the same agar plate, only one isolate was 
retained for the collection. In addition, if more than one identical colony of a filamentous fungi 
were growing on the same agar plate plated with soil, only one colony was retained for the 
collection. Thus, it is not possible to easily determine from the fungal libraries if species that were 
readily culturable are more or less represented in the control or treated soils as the enrichment 
process would distort counts of yeasts. Nonetheless, although yeasts were not tallied by 
morphology noted per agar plate, in certain instances, when each soil was directly plated onto agar, 
it was clear that colonies of certain morphologies were less prevalent on plates containing high 
treatment soils compared to control soils. For example, red pigmented colonies were observed on 
all four DG agar plates plated with control soil on but were not observed on any of the four plates 











4.2 No evidence of increased azole resistance in isolates 
from azole-containing soil  
 
As shown by the disk diffusion assays, in general, yeasts and filamentous fungi isolated from the 
soils receiving clotrimazole and miconazole were not detected to be any more or less sensitive to 
the tested azoles when compared to isolates from the control plots. This pattern held when looking 
at all isolated yeasts or filamentous fungi from a soil treatment type and when looking at specific 
species, such as the yeast Cyberlindnera saturnus and Rhodotorula mucilaginosa and the 
filamentous fungi Clonostachys rosea and Rhizomucor variabilis. However, some statistical tests 
did show significant differences in sensitivities between sensitive isolates from different 
treatments, as determined by smaller average zones of inhibition. For example, in the case of 
difenoconazole, isolates from the low treatment appear to be more resistant to those from the 
control with an average zone of inhibition nearly 10 mm smaller (p=0.0004) while the isolates 
from the high treatment were not any more resistant (p=0.11). It could be argued that these p-
values are affected by low statistical power of the tests, as the average zone of inhibition from the 
low treatment isolates was 34.3 ± 9.5 mm versus 42.4 ± 9.9 mm for the isolates from the control, 
which puts the two averages within the 20% error range for ZOI measurements (Table 4.0; Table 
6). 
 
4.3 Susceptibilities of tested species versus literature values 
 
Similar to the results from this study showing all R. mucilaginosa isolates being sensitive to 
clotrimazole, an analysis of 72 strains of Rhodotorula–including five strains of R. mucilaginosa–
from hospitals in Iran (Seifi et al., 2013) in addition to five R. mucilaginosa strains from pigeon 
feces in Saudi Arabia (Abulreesh et al., 2019) showed all R. mucilaginosa strains being sensitive 
to clotrimazole. In this study, 80.5% of Rhodotorula isolates were considered to be weakly 
susceptible to the miconazole disks, with an additional 17% being considered resistant and a single 
isolate being classified as sensitive. Likewise, a study of 30 clinical Rhodotorula strains–21 of 
them being R. mucilaginosa—from French hospitals found that miconazole was the only drug of 





‘intermediate’ (Preney et al., 2003). The clinical strains from Iran also showed a range of 
sensitivities to miconazole, especially with R. mucilaginosa (Seifi et al., 2013). 
 
In comparison to the relatively few Rhodotorula isolates tested to the medical imidazoles in the 
literature, much more information exists on the sensitivity of clinical Rhodotorula isolates to the 
medical triazoles. A review of 131 Rhodotorula isolates tested using the established NCCLS and 
EUCAST methods, in addition to the commercially-available agar-based Etest and the microbroth 
dilution-based Sensititre YeastOne tests, concluded that fluconazole, voriconazole, and 
itraconazole were inactive against the majority of tested isolates (Gomez-Lopez et al., 2005). The 
MIC90 values for 29 isolates tested by the reviewers were found to be >64, 8, and 8 mg/L to 
fluconazole, itraconazole, and voriconazole, respectively. This is in accordance with this study, 
which ultimately classified all Rhodotorula isolates as resistant to fluconazole, 85.4% of isolates 
being resistant to voriconazole with the remaining being weakly susceptible, and 78% of isolates 
being resistant to itraconazole with 14.6% being weakly susceptible and 7.3% being susceptible.  
 
Nonetheless, previous studies have noted several differences between clinical and non-
clinical Rhodotorula strains. For example, while clinical Rhodotorula strains are frequently noted 
as fluconazole-resistant (Tuon & Costa, 2008), the Rhodotorula strains from pigeon feces in Saudi 
Arabia were noted for their susceptibility to fluconazole (Abulreesh et al., 2019), a result shared 
with five Rhodotorula strains isolated from bird feces in Malaysia (Lord et al., 2010). In addition, 
a sample of clinical isolates was shown to have greater biofilm capacity compared to 
environmental isolates (Nunes et al., 2013). As for sensitivity to agricultural azoles, a 
metagenomic study of pear fruit fields treated with various fungicides, including azoles such as 
difenoconazole and tebuconazole, found that the proportion of Rhodotorula isolates, primarily 
represented by R. glutinis, increased in the fungicide-treated fields compared to control fields, 
which suggests relative resistance to these drugs (Zambounis et al., 2020).   
 
As for isolated filamentous fungi, Actinomucor elegans, Mortierella alpina, Mucor circinelloides, 
and Rhizomucor variabilis were isolated from the soils and were expected to be resistant to the 
azole drugs. These species belong to the Mucoromycotina order, which causes the highly-lethal 





F5 confers resistance to certain azoles, such as voriconazole and fluconazole, but not others, such 
as itraconazole (Caramalho et al., 2017). The mechanism of resistance to the former drugs and 
sensitivity to itraconazole has been elucidated to involve a tertiary hydroxyl group that interferes 
with hydrogen bonding between the azole drug and the lanosterol 14a-demethylase enzyme 
(Sagatova et al., 2016). Sun et al. reported that MIC values, as determined by CLSI microbroth 
dilutions, for seven clinical Mucor sp. were all above 64 μg/mL for fluconazole and ranged 
between 32-64 μg/mL for voriconazole (Sun et al., 2002). Meanwhile, the MIC values toward 
itraconazole ranged from 0.25-8 μg/mL (Sun et al., 2002). 
 
As expected, given the data from the literature, isolated Mucor circinelloides (n=2) 
and Rhizomucor variabilis (n=9) were resistant to fluconazole and voriconazole and weakly 
susceptible to miconazole and itraconazole. Interestingly, however, the isolates were clearly 
susceptible to clotrimazole. In a preliminary test, a single tested M. circinelloides isolate from the 
high treatment plots showed sensitivity to difenoconazole and tebuconazole and resistance to 
propiconazole. This finding could be useful as Mucor rot has been described as an emerging 
postharvest disease caused by Mucor spp. affecting multiple crops, such as mandarin oranges in 
California (Saito et al., 2014). Resistance of the species Mucor rouxii to propiconazole has 
previously been described (Weete & Wise, 1987). 
 
4.4 Spectrums of activity and co-resistance between azoles  
 
A previous study analyzed the antifungal susceptibility of 1,698 yeasts from various sources 
(Desnos-Ollivier et al., 2012). The study defined isolates with a high MIC as being able to grow 
in ≥8 ug/mL fluconazole, ≥0.25 ug/mL voriconazole, and ≥0.5 ug/mL of itraconazole. 
Fluconazole was effective against the smallest proportion of environmental isolates, with 45% 
having a high MIC toward the drug, while only 18-21% of environmental isolates had a high 
MIC against voriconazole or itraconazole. The study also made the surprise finding that, when 
considering isolates from all origins, which included isolation from human, food, and industrial 
sources, Basidiomycetes were more likely to yield a high MIC to the three drugs than 







In agreement with the study, as shown in Figure 12.0, a higher proportion of isolates were 
resistant to fluconazole than the other two tested medical triazoles. In addition, of the tested 
medical imidazoles, clotrimazole was effective against a larger proportion of isolates compared 
to miconazole, which agrees with a previous study of yeasts with medical significance 
(Yamaguchi et al., 1983). When broken down by phylogeny, 82 Basidiomycete yeasts strains 
were tested against the medical azoles with 8.5% and 26.8% being resistant to the imidazoles 
clotrimazole and miconazole, respectively, and 15.8%, 69.5%, and 95.1% being resistant to the 
triazoles itraconazole, voriconazole, and fluconazole, respectively. On the other hand, of 63 
Ascomycete yeasts, all were susceptible to the medical azoles with the exception of two isolates 
of Debaryomyces to fluconazole. All isolated filamentous fungi, except for the Mucormycetes, 
belonged to the Ascomycota. 
 
One unexpected finding from the azole sensitivity tests was that co-resistance to clotrimazole and 
miconazole was not widely noted either in isolates obtained from the control plots or from the 
plots receiving annual applications of clotrimazole and miconazole (Table 5.0; Supplementary 
Table 3.9). Of the seven clotrimazole-resistant yeasts, one isolate identified as Filobasidium 
oeirense and four isolates identified as Tausonia pullulans were sensitive to miconazole while two 
isolates identified as Bullera alba were resistant to both drugs. On the other hand, most isolates 
of Sampaiozyma ingeniosa were miconazole-resistant and only weakly susceptible to clotrimazole 
while Rhodotorula mucilaginosa isolates were commonly miconazole-resistant while being 
clearly susceptible to clotrimazole. With respect to filamentous fungi, the fact that the tested 
Mucormycetes were sensitive to clotrimazole but not the other tested azole drugs lends further 
evidence that the spectrum of activity of clotrimazole is significantly different from that of the 
other clinical azoles. Overall, it was clear that, miconazole-resistant isolates were not likely to be 










4.5 Isolates with little prior azole documentation 
 
As for the identified isolates determined to be very susceptible to miconazole, the azole-
susceptibilities of the corresponding species have not been well-described in the literature. There 
were no previous reports of the susceptibility of Sampaiozyma ingeniosa to the tested azoles 
and Cutaneotrichosporon terricola, Schwanniomyces occidentalis, Solicoccozyma aeria, 
and Mrakia spp. to any azole in the literature. Of note, the disk diffusion assays were performed 
at either 15°C or 30°C, while previous studies of environmental antifungal resistance tend to focus 
on yeasts with medical or agricultural significance or those that can grow readily during testing. 
For example, Maciel et al. did not test the azole susceptibility of Cutaneotrichosporon 
terricola due to its inability to grow at 37°C (Maciel et al., 2019), and the disk diffusion assay 
performed by Perini et al. where Mrakia spp. isolates were grown on SD agar for four days and 
then tested on RPMI-glucose agar at 15°C for 2-7 days failed due to a lack of growth on test plates 
(Perini et al., 2019). However, in this study, growing Mrakia isolates for seven days on SD agar 
and then performing a four-day disk diffusion assay on RPMI-glucose agar plates, both at 15°C, 
successfully allowed for azole susceptibility testing of 4 out of 6 Mrakia isolates. 
 
On the other hand, a previous mycobiome sequencing study of the wheat phyllosphere mycobiome 
after application of Viverda, an agricultural fungicide containing epoxiconazole in addition to 
fungicides from other classes, identified V. victoriae as being the most susceptible species to the 
effects of the fungicide (Knorr et al., 2019). Disk diffusion assays using the difenoconazole, 
propiconazole, and tebuconazole disks on the same plate failed twice with indications of large 
zones of inhibition only appearing after six-days of incubation. The findings from this study, as 
well as the findings from the disk diffusion assay, indicate that this species may be hyper 
susceptible to azoles. 
 
A literature review yielded few results on the antifungal susceptibility of several other species 
isolated and tested in this study. For example, the sole reference for the antifungal susceptibility 
of C. saturnus comes from a single isolate obtained from Piracicaba River, Brazil that was tested 
against a panel of drugs, including fluconazole and itraconazole, using a broth microdilution test 





(0.25 µg/mL) marking relative resistance and susceptibility to the drugs, respectively, similar to 
the results obtained in this study (Medeiros et al., 2008). However, when tested by disk diffusion 
assays, C. saturnus isolates showed trailing endpoints toward all tested azole drugs and continued 
growth within the zones of inhibition following the standard disk diffusion assay. Thus, C. 
saturnus may be more resistant to azole drugs than suggested by both studies. The azole 
susceptibility of C. saturnus may be of future interest due to its previously described abundance 
in soils and ability to promote plant growth. 
 
4.6 Isolates with human pathogenic potential 
 
A previous analysis of 5,000 yeasts from 1,000 environmental samples yielded 54 strains of 
budding yeasts with human pathogenic potential and found that pathogenic yeasts were associated 
with soils compared to other sampling locations such as fruit, leaves, and wood (Opulente et al., 
2019). This study, on the other hand, yielded relatively more isolates classified as opportunistic 
human pathogens including yeasts, such as Rhodotorula mucilaginosa, that are not classified as 
‘budding yeast'. 
 
Debaryomyces hansenii and Rhodotorula mucilaginosa are two opportunistic human pathogens 
that are commonly isolated from environmental sources. D. hansenii (syn. Candida famata) is 
particularly associated with dairy products as well as being a cause of infections of the 
bloodstream, peritoneum, retina, and tissue of the mid-chest (reviewed in Beyda et al., 2013). The 
ARTEMIS global antifungal surveillance program found that of over 250,000 
clinical Candida isolates collected globally between 1997 and 2007, 0.3% were identified 
as Candida famata (Pfaller et al., 2010). In addition, C. famata was isolated from 2.1% of 642 
blood samples producing fungal isolates at Teikyo University Hospital, Japan between 1979 and 
1995 (Kawakami et al. 1980). Although being a rare cause of infections, at least one case of 
invasive infection has been detected in a patient with no underlying conditions or risk factors 
(Wong et al., 1982). On the other hand, clinical infection of D. hansenii may be subject to 
overestimation due to misidentification of Pichia guilliermondii (syn. Candida guilliermondii) as 






Another candidiasis-causing yeast, Diutina catenulata (syn. Candida catenulata) was isolated 
from a control plot. The species is commonly isolated from environmental samples, particularly 
dairy products, and is a rare cause of invasive infections in immunocompromised hosts 
(Radosavljevic et al., 1999). 
 
Rhodoturla mucilaginosa has been described as an emerging opportunistic pathogen (Pfaller & 
Diekema, 2004; Wirth & Goldani, 2012). As reviewed by Wirth & Goldani 
(2012), Rhodotorula species are ubiquitous in the environment, having been isolated from 
environmental samples, such as air, soil, and food products, as well as being detected as the most 
common microorganism from the hands of hospital workers. R. mucilaginosa is also a common 
contaminant of catheters due to its strong affinity for plastic. It follows that most cases of infections 
involve central venous catheter (CVC) use and, most likely due to the increase in CVC use, reports 
of infections have increased in haematological patients since 1985. Infections can also, especially 
in HIV-positive patients, lead to serious complications such as meningitis and endophthalmitis 
(Wirth & Goldani, 2012). Overall, Rhodotorula was found in 4.2% of clinical isolates (n=8821) in 
the ARTEMIS project, being the 4th-most common non-Candida yeast (Pfaller, Diekema, et al., 
2009). 
 
No other yeasts of clinical relevance was identified in the collection. Although some case studies 
note Tausonia pullulans (syn. Trichosporon pullulans) as a cause of trichosporonosis in 
immunocompromised hosts, reports of T. pullulans infections may be due to misidentification 
(Holland et al., 2004). 
 
For filamentous fungi, the most clinically relevant group isolated from the soils 
was Aspergillus spp., which cause a group of diseases called aspergillosis. Aspergillosis can 
present as respiratory infections as spores of the fungi are introduced into the lungs. Patients with 
asthma or cystic fibrosis can suffer from allergic bronchopulmonary aspergillosis, which is an 
allergic reaction to the fungi that can damage lung tissue (Latgé, 1999). In addition, those with 
pre-existing lung conditions can suffer from aspergilloma, balls of the fungi in the lungs, which 
are commonly asymptomatic but can also lead to fatal internal bleeding due to disrupted blood 





immunocompromised patients with severity and symptoms depending on the organ infected and 
the underlying condition (Latgé, 1999). 
 
In addition, Purpureocillium lilacinum has been noted for causing invasive infections in 
immunocompromised patients. The fungus can spread quite readily, for example, in contaminated 
lotion in a hospital (Orth, 1996). Spores of the species are used in the agricultural setting as a 
biocontrol agent where it has been suggested that they pose a risk to immunocompromised people 
(Luangsa-Ard et al., 2011). The species can cause serious eye infections, such as keratitis and 
endophthalmitis, in those who wear soft contact lenses or have trauma to the eyes (Todokoro et al. 
2014) and can also cause dermatological infections without predisposing conditions (Saghrouni et 
al., 2013). 
 
Fusarium species are found in environmental samples, such as soil and air, and are opportunistic 
human pathogens. For immunocompetent people, Fusarium infections can cause onychomycosis 
in those that walk outdoors with exposed toenails, cutaneous infections for burn victims, and 
keratitis for contact lens users. On the other hand, in cancer patients, those with severe burns, or 
organ transplant patients, skin, lung, and sinus infections can develop (Dignani & Anaissie, 2004). 
In institutions monitoring severely immunocompromised patients, such as cancer patients and 
marrow transplants, Fusarium infections were documented at incidences of around 0.2-1.2% of 
patients (Dignani & Anaissie, 2004). 
 
Other isolated filamentous fungi have been identified as the causative agent of an infection only 
recently. For the first time, in 2017, Chowdhary et al. reported Penicillium oxalicum as the cause 
of invasive infections in three cases involving immunocompromised patients (Chowdhary et al., 
2017). In addition, for the first time, in 2020, Masetti et al. reported Albifimbria verrucaria as the 










4.7 Isolates with notable agricultural relevance 
 
The two most commonly isolated yeasts from the soils, Cyberlindnera saturnus and Rhodotorula 
mucilaginosa, have previously been studied for their association with crops, especially with 
respect to their ability to promote plant growth. The first report of an auxin-producing endophytic 
yeasts was for an isolate of Cyberlindnera saturnus (syn. Williopsis saturnus). This endophyte of 
maize roots was found to produce the plant growth promoting hormones indole-3-acetic acid and 
indole-3-pyruvic acid in vitro and increase root and shoot growth of maize following seedling 
inoculation (Nassar et al., 2005). Isolates of R. mucilaginosa have been found to be endophytes of 
cottonwood and produce indole-3-acetic acid (Xin et al., 2009). 
 
Compared to the isolated yeasts, the isolated filamentous fungi strains have been documented more 
thoroughly for agricultural relevance, where they range from pathogenic to growth-promoting. For 
example, species in the Fusarium solani complex are a cause of sudden death syndrome of 
soybeans in North America (Aoki et al., 2003), while those in the F. oxysporum complex can cause 
root rot and seedling blight (Lanubile et al., 2015). On the other hand, it has been shown that 
inoculation of seeds and subsequent colonization of maize plants with Metarhizium robertsii leads 
to higher above-ground biomass, suppression of growth of black cutworm larvae on leaves, and 
alteration expression of plant defense genes (Ahmad et al., 2020). Strains of Clonostachys 
rosea have been reported to cause root rot in soybeans (Bienapfl et al., 2012) while strains have 
also been positively associated with suppression of Sclerotinia sclerotiorum, the fungal pathogen 
causing white mould, and increased shoot length upon inoculation (Rodríguez et al., 2015). 
 
4.8 Future experiments and closing remarks 
 
Given the number of filamentous fungi recovered with medical and agricultural significance, 
future experiments can test the recovered filamentous fungi to medical triazoles and agricultural 
triazoles. In addition, while initial colony counts were performed on agar containing 1 mg/L 
clotrimazole and 1 mg/L miconazole, little growth was observed on plates (Figure 10). Thus, future 





concentrations of the drugs to obtain suitable plate counts. These plate counts can be used to see 
if the treated soils contain more azole-resistant isolates than the untreated soils. In addition, replica 
plating from agar containing no azole drugs to agar containing miconazole can be used to further 
test the hypothesis that the control soils contain more isolates that are highly susceptible to 
miconazole. Finally, in order to see if any particular species shows differential abundance between 
the control and treated soils, targeted plate counts could be used. For example, Debaryomyces 
hansenii isolates can be selectively grown in conditions of 5% glucose and 10% NaCl (Breuer & 
Harms, 2006) and Rhodotorula species can be readily identified by pink-red colonies on SD agar. 
In addition, qPCR assays can also be used. Assays have already been published for 
quantifying Cystofilobasidium infirmominiatum (Spotts et al., 2009), a yeast isolated from the 
control and low treatment plots but not the high treatment plots, and Vishniacozyma 
victoriae (Rush et al., 2020), a yeast found to be highly susceptible to miconazole and the 
agricultural fungicide Vividera. In addition, assays for quantifying the medically and agriculturally 
important filamentous fungi Mucor circinelloides and Clonostachys rosea also exist (Bernal-
Martinez et al.; Gimeno et al., 2019). Microbial community profiling using next-generation 
sequencing techniques can also further elucidate changes in community composition between the 
treated and untreated soils. 
 
Overall, it was found that soils amended with environmentally-relevant concentrations of 
miconazole and clotrimazole showed reduced fungal load and diversity compared to control soils. 
While notable changes in azole susceptibility were not detected among the fungal isolates from 
the treated versus control soils, there was some indication that the treated soils contained fewer 
isolates highly susceptible to miconazole. Given the isolation of medically and agriculturally 
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6 Appendix A 
Supplementary Table 1 – Partial ITS Sequences of Yeasts  












































































































































































































































































Supplementary Table 2 – Partial ITS Sequences of Filamentous Fungi 























































































































































































































































   
 
Supplementary Figure 1 – Examples of Disk Diffusion Assay Interpretations 
The shown Cyberlindnera saturnus isolate (left) was determined to be sensitive to clotrimazole 
and miconazole (top rows), as well as itraconazole (bottom right), but resistant to fluconazole 
(bottom left), and weakly susceptible to voriconazole (bottom centre). The zone of inhibition 
measurement for voriconazole, which showed trailing growth, was determined by measuring from 
the edges of the apparent start of the trailing growth and is illustrated here by the red bar.  Likewise, 
the shown Debaryomyces hansenii isolate (middle) was determined to be resistant to fluconazole 
(bottom left) due to the normal-sized colonies within a zone of 70 mm from the disk. Also, the 
ZOI against clotrimazole and itraconazole for the shown Sampaiozyma ingeniosa isolate (right) 
was determined to be between 70 and 150 mm due to small zones of inhibition reaching just below 
150 mm to each disk. 
 
Supplementary Table 3 – Contingency Tables used for Fisher Exact Tests, Analysis of 
Drug Cross-resistance 
 
3.1 - Number of sensitive 
and resistant isolates to 
clotrimazole, voriconazole, 
or both drugs* 
 
3.2 - Number of sensitive and 
resistant isolates to 
miconazole, voriconazole, or 
both drugs* 
 
3.3 - Number of sensitive 
and resistant isolates to 
fluconazole, voriconazole, or 
both drugs* 
  VRCS VRCR 
 
  VRCS VRCR 
 
  VRCS VRCR 
CTZS 81 46 
 
MCZS 81 30 
 
FCZS 46 0 
CTZR 1 7  MCZ
R 1 22  FCZ
R 36 52 
           
3.4 - Number of sensitive 
and resistant isolates to 
voriconazole, itraconazole, 
or both drugs* 
 
3.5 - Number of sensitive and 
resistant isolates to 
propiconazole, itraconazole, or 
both drugs* 
 
3.6 - Number of sensitive 
and resistant isolates to 
itraconazole, fluconazole, or 
both drugs 
  ITRS ITRR 
 
  PROS PROR 
 
  ITRS ITRR 
VRCS 52 1 
 
VRCS 73 0 
 
FCZS 46 0 
VRCR 39 14  VRC
R 26 7  FCZ
R 74 14 
   
 
   
 





3.7 - Number of sensitive 
and resistant isolates to 
miconazole, fluconazole, 
or both drugs  
3.8 Number of sensitive and 
resistant isolates to 
miconazole, itraconazole, or 
both drugs  
3.9 - Number of sensitive 
and resistant isolates to 
clotrimazole, miconazole, or 
both drugs 
  FCZS FCZR    ITR
S ITRR    MCZ
S MCZR 
MCZS 41 72  MCZ
S 110 5  CTZ
S 121 20 
MCZR 0 47  MCZ
R 13 10  CTZ
R 5 3 
   
 
   
   
  
3.10 - Number of sensitive 
and resistant isolates to 
clotrimazole, fluconazole, 
or both drugs*  
3.11 - Number of sensitive and 
resistant isolates to 
clotrimazole, itraconazole, or 
both drugs*  
3.12 - Number of sensitive 
and resistant isolates to 
propiconazole, clotrimazole, 
or both drugs* 
  FCZS FCZR 
 
  ITRS ITRR 
 
  PROS PROR 
CTZS 46 80  CTZ
S 158 12  CTZ
S 97 3 
CTZR 0 8  CTZ
R 6 2  CTZ
R 1 4 
   
 












3.13 - Number of sensitive 
and resistant isolates to 
propiconazole, miconazole, 
or both drugs*  
3.14 - Number of sensitive and 
resistant isolates to 
propiconazole, voriconazole, 
or both drugs  
3.15 - Number of sensitive 
and resistant isolates to 
propiconazole, fluconazole, 
or both drugs 
  PROS PROR 
 
  PROS PROR 
 
  PROS PROR 
MCZS 88 1  ITR
S 79 6  FCZ
S 9 0 
MCZR 8 6  ITR
R 7 1  FCZ




















Supplementary Table 4 – Contingency Tables used for Fisher Exact Tests, Analysis of 
Isolates Highly Susceptible to Miconazole 
 
4.1 - Number of highly 
susceptible isolates to 
miconazole isolated from 
the control versus the low 
treatment plots  
4.2 - Number of highly 
susceptible isolates to 
miconazole isolated from 
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